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1.1 The Post-genomic vaccine development 
For over a century, vaccines were developed according to Pasteur’s 
principles of isolating, inactivating and injecting the causative agent of an 
infectious disease. The availability of a complete microbial genome sequence 
in 1995 marked the beginning of the genomic era that allowed scientists to 
change the approach for vaccine development starting from genomic 
information; this process was named “reverse vaccinology” (Fig.1).  
This can be considered as one of the most powerful examples of how genomic 
information can be used to develop therapeutic interventions, which were 
difficult or impossible to obtain with conventional approaches used in the past 
to produce vaccines. The latter approaches were based indeed on the 
cultivation of the microorganism in laboratory conditions from which single 
components were isolated individually by using biochemical, microbiological 
and serological methods. Each antigen was produced in pure form either 
directly from the bacterium or using the recombinant DNA technology, and 
finally tested for its ability to induce an immune response. However, although 
successful in many cases, this approach presented several limitations. 
This approach needed to grow the pathogen in vitro, so not applicable to 
uncultivable microorganisms, and in many cases the antigens expressed 
during infection are not produced in laboratory conditions. Moreover, the 
proteins that are most abundant and easily purified are not necessarily 
protective antigens and, in any case, only a few molecules can be isolated and 
tested simultaneously. In conclusion, this method can employ many years to 
identify a protective and useful antigen, and has failed to provide a vaccine 
against those pathogens that did not have obvious immunodominant protective 
antigens.  
As the genomic era progressed, it becomes apparent that multi-strain 
genome analysis is fundamental to the design of universal vaccines. The 
availability of the complete genome of microorganisms combined with novel 
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genome-based approaches (proteomic and microarray analysis) has 
introduced new perspectives in vaccine research (1). 
For the first time, the genome sequences represent an inclusive virtual 
catalogue of all the potential vaccine candidates from which it is possible to 
select the molecules that are likely more effective, regardless of their 
abundance, or if they are expressed in vivo or in vitro conditions. Pan-genome 
approach represents an advance in the use of reverse vaccinology, since it 
highlights the potential of looking at more than one genome for the same 
bacterial species to overcome the problems represented by gene presence 
and variability (Fig.1). 
In the post-genomic era the next challenge of the vaccines study is the 
merging of the vaccinology with structural biology (1). 
1.1.2 The future of the vaccinology:  the structural approach 
Structural genomics, a high-throughput application of structural biology 
which utilizes X-ray crystallography or nuclear magnetic resonance (NMR) 
spectroscopy for protein structures determination, is increasingly being applied 
to vaccines and drugs development as a result of the explosion of genome and 
proteome data, and has provided continuing improvements in the fields of 
protein expression, purification, and structural determination (2). 
Structural biology studies in the past few decades allowed the identification 
and understanding of many basic principles of proteins, nucleic acid structures, 
molecular machines and viruses. Besides, structural biology demonstrated to 
have enormous biomedical applications; indeed structure-based development 
of drugs is already well integrated into the pharmaceutical industry and lead to 
the identification of important drugs. 
Structural biology can also significantly aid the rational design of future 
vaccines. The application of structural biology principles in the vaccinology 
field resulted in the creation of a powerful new approach named structural 
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vaccinology (Fig. 1), which gave a tremendous help in the development of 
vaccines against diseases that we could not defeat using other approaches.  
Structural studies allow indeed the atomic resolution of the structures of 
potential antigens and, through their structure, the rational design of target 
epitopes to use as vaccine candidates will be performed.  
Several examples of the application of structural biology to the design of 
effective vaccines are already in place against several pathogens that most 
heavily afflict global health, like for example meningococcus. 
 
 
 
Figure 1. The vaccinology field. Past: Conventional approaches to produce 
vaccines. Present: The genomic era has completely changed the way to 
design vaccines (Reverse Vaccinology); Future: The structural biology applied 
to vaccinology (Structural Vaccinology) (Rappuoli, 2006). 
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1.2 Historical background  
 The discovery that various diseases are caused by microorganism 
occurred in twilight of nineteenth century and symbolized a milestone in the 
studies of infectious diseases. In 1879 Louis Pasteur demonstrated the link 
between microbiological organisms and puerperal sepsis. 
Description of illness resembling meningococcal disease dates back to the 
16th century. It was first described by Vieusseux in 1805 after an epidemic of 
meningitis in Geneva (3) and in 1882 the pathogen responsible for this illness 
was first isolated from the cerebrospinal fluid (CSF) of an infected patient by 
the Italian pathologists Marchiafava and Celli (4). 
Anton Weichselbaum in 1887 first identified the bacterium causing 
meningococcal disease in the CSF of six of eight patients of bacterial 
meningitis and the bacterium was named  Neisseria intracellularis (5). 
In 1909, immunologically distinct serotypes of the meningococcus were 
identified. This established the basis for serum therapy, which was instituted in 
1913 by Flexner in the USA and through which mortality was reduced from 
nearly 100% to 30% (6, 7). 
Subsequently the discovery of sulfonamides and other antimicrobial agents 
dramatically reduced the incidence of meningitis and the advent of penicillin G 
greatly improved the treatment of meningococcal meningitis and sepsis, 
resulting fundamental in decreasing mortality rates. 
 Despite treatment with appropriate antimicrobial agents and optimal medical 
care, the overall case fatality rates remained relatively stable over the past 20 
years, at 9 to 12%, with a rate of up to 40% among patients with 
meningococcal sepsis (8). 
About the 20% of survivors of meningococcal disease have sequelae, such as 
hearing loss, neurological disability, or loss of a limb (9). 
1.3 Microbiology and Epidemiology 
Neisseria meningitidis is a Gram-negative, capsulated, aerobio diplococco, 
member of to the bacterial family Neisseriaceae. It is surrounded by an outer 
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membrane composed of lipids, outer membrane proteins (OMPs) and 
lipopolysaccharides. Pathogenic meningococci are enveloped by a 
polysaccharide capsule attached to this outer membrane. Neisseria 
meningitidis is the major cause of bacterial septicemia and the most common 
cause of bacterial meningitis, that can have catastrophic consequences in 
individuals and can become epidemic in developed and developing countries 
(Buysse et al 2008). Meningococci can be classified on the basis of the 
chemical composition of different capsular polysaccharide structures into 13 
serogroups: A, B, C, H, I, K, L, M, W135, X, Y, Z and 29E (serogroup D is no 
longer recognized). Among them, only five (A, B, C, Y and W135) have been 
associated with the disease and so considered as pathogenic serogroups. 
Meningococci are further classified into 20 serotypes and 10 subtypes (on the 
basis on the antigencity the outer membrane porins PorA and PorB ) and 13 
immunotypes (on the basis of lipooligosaccharide  structure) (10, 11, 12). 
Meningitis is an inflammatory disease of the leptomeninges, the tissues 
surrounding the brain and spinal cord. The meninges consist of three parts: the 
pia, arachnoid, and dura matres. Meningitis reflects inflammation of the 
arachnoid mater and the cerebrospinal fluid (CSF) in both the subarachnoid 
space and in the cerebral ventricles. 
 
Epidemic rates of meningococcal disease varies from <1-3/100,000 in many 
developed nations to 10-25/100,000 in some developing countries. This 
difference in attack rates reflects the difference in pathogenic properties of N. 
meningitidis strains and differences in socioeconomic and environmental 
conditions. The proportion of cases caused by each serogroup varies by age 
group; more than half of cases among infants aged <1 year are caused by 
serogroup B, for which no vaccine is available (13, 14). 
Of the five common pathogenic serogroups (A, B, C, Y and W135) responsible 
for about 90% of infections caused by N. meningitidis, serogroups A, B and C 
account for most cases of meningococcal disease throughout the world, with 
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serogroups A and C predominating in Asia and Africa and serogroups B and C 
responsible for the majority of cases in Europe and the Americas (15, 16, 17, 
18, 19) (figure 2). 
 
 
 
Figure 2.  
Worldwide distribution of major meningococcal serogroups (Sthephens, 2007). 
 
Rates of meningococcal disease are highest for young children at 6 to 24 
months of age, when maternal antibody has disappeared and increase for 
adolescents and young adults. In endemic situations serogroup B is most 
common in infants, serogroup C in adolescents and serogroup B and Y in 
older adults. 
1.4 Classification and Antigenicity 
Meningococcal virulence is related to several factors, such as capsular 
polisaccharide, outer membrane proteins (OMPs) and endotoxin or lipo-
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oligosaccharide (LPS). A schematic representation of bacterial compartment 
and of main components is reported in Figure 3. 
 
 
 
Figure 3. Section of the Meningococcal cell membrane. 
 
The polysaccharide capsule, which covers the bacterium surface, is the major 
virulence factor. It is a homopolymer or a heteropolymer consisting of 
monosaccharide, disaccharide, or trisaccharide repeating units. Except for 
serogroup A, the capsules are composed of sialic acid (N- acetyl neuraminic 
acid, NANA) derivatives. 
The peculiarity of the membrane is to allow  the bacterium to survive in the 
blood stream and to confer resistance to phagocytosis and complement-
mediated lysis. As a consequence, acapsulated bacteria are inactive in vivo 
since cannot persist in the blood.  
The outer membrane is composed by many proteins that contribute to 
meningococcal virulence, such as Pili which are filamentous structures located 
on the meningococcus surface, essential in mediating the initial interaction of 
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meningococci and both epithelial and endothelial cells. Meningococcus also 
expresses variable proteins such as Opa and Opc, which are important in 
adhesion to and invasion into eukaryotic cells and outer membrane porins, 
PorA and PorB, which are involved in host-cells interaction and as target for 
bactericidal antibodies.  
1.5 Mechanisms of infection 
The human naso-oropharyngeal mucosa is the only natural reservoir of N. 
meningitidis. 
Three crucial steps are involved in the development of the disease: 
1. The crossing by the bacterium of the mucosal barrier; 
2. The invasion in the blood stream; 
3. The crossing of the blood-brain-barrier and final reaching of the 
meninges. 
 
Meningococci are transferred from one person to another by direct contact or 
via droplets for a distance up to 1 m. During periods of endemic infection, 8 to 
20% of adults are asymptomatic nasopharyngeal carriers of strains of N. 
meningitidis, most of which are not pathogenic (20, 21). 
The duration of meningococcal carriage can vary from days to many months. 
Only under particular conditions and in susceptible individuals, N. meningitidis 
penetrates the mucosa and gains access to the bloodstream, causing systemic 
disease (22). In most persons, nasopharyngeal carriage is an immunizing 
process, resulting in a systemic protective antibody response (23).  
A general scheme of the steps of invasion of meningococcus is shown on 
figure 4. 
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Figure 4. 
Colonization of nasopharinx by N. meningitidis and entry into the bloodstream 
and cerebrospinal fluid (Rosenstein, 2001). 
 
From the bloodstream, the bacterium can cross the blood-brain barrier and 
spreads to the celebrospinal fluid, causing meningitis. The mechanisms behind 
the propensity of meningococci to invade the meninges and their passage 
across the blood-brain barrier are poorly understood. Neurological damage in 
meningitis may be caused by a mixture of direct bacterial toxicity, indirect 
inflammatory processes and cerebral oedema. 
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1.6 Clinical manifestations, treatment and prevention 
Initial general symptoms like fatigue, fever and headache, can rapidly progress 
to septicemia, coma and death, which arises predominantly by celebral 
oedema. 
Currently an antibiotic therapy represent the elected treatment for meningitis, 
since effective antibiotics immediately stop the proliferation of bacteria. 
Antibiotic therapy should be started as early as possible, in order to avoid the 
bacteria proliferation and the progression of internal lesions. Benzylpenicillin, 
cefotaxime, ceftriaxone and chloramphenicol are effective antibiotics.  In 
particular Chloramphenicol is bactericidal for meningococcus and penetrates 
the blood brain barrier more effectively. 
1.7 Vaccines 
Although antimicrobial therapy has contributed to reduce the mortality rate of 
65-80%, cases of fulminant meningococcemia are unfortunately generally 
hopeless. 
Prevention of disease can effectively be accomplished by vaccination. 
Immunization was made possible in 1969 when it was discovered that 
protection from disease correlates with the presence in the serum of antibodies 
able to induce complement-mediated killing of bacteria, and that purified 
capsular polysaccharide was able to induce them. 
Tetravalent vaccines against serogroups A, C, W-135, and Y have been 
available since 1984 (24, 25). 
Although efficacious in adolescents and adults, this vaccine is poorly 
immunogenic in infants and do not induce immunological memory. 
Unfortunately, the conjugate approach cannot be easily applied to serogroup B 
(26) because the B capsular polysaccharide is a polymer of N-acetyl 
neuraminic acid or polysialic acid, a molecule which is identical to a widely 
distributed human carbohydrate. Being the serogroup B polysaccharide 
identical to a self-antigen, man is immunologically tolerant to it and therefore it 
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fails to induce an effective immune response. On the other hand, an immune 
response against it would risk to induce autoimmunity (27, 28). 
To develop a vaccine against serogroup B, surface-exposed proteins 
contained in outer membrane vesicles (OMVs) have been used (29, 30). 
These vaccines elicit serum bactericidal antibody responses and protect 
against meningococcal disease (31, 32). However, while they induce 
complement-mediated bactericidal antibodies against the homologous strain, 
they fail to induce bactericidal antibodies against heterologous strains (33). 
Today, the development of vaccines against serogroup B (which is responsible 
for 40% of all cases in USA  and 45-80% in Europe) remains a challenge, 
since  conventional biochemical and microbiological approaches have so far 
failed. 
1.7.1 The Reverse vaccinology 
The availability of the whole genome has permitted the development of a new 
strategy called “reverse vaccinology” (34): the genome represents a list of 
virtually of all the protein antigens that a pathogen can express at any time. It 
becomes possible to choose potentially surface exposed proteins in a reverse 
manner, starting from the genome rather than from the microorganism, with 
the great advantage that cultivation of dangerous microorganisms is not 
needed anymore. Consequently the process can be equally applied to 
cultivable and non-cultivable microorganisms. 
This approach, starting from the genomic sequence by computer analysis, 
predicts those antigens that are most likely to be vaccine candidates (34). The 
feasibility of the approach relies heavily on the avaibility of a high-throughput 
system to screen protective immunity. 
On figure 5  a general scheme of the steps describing the reverse vaccinology 
is represented.   
Fragments of DNA are screened by computer analysis and novel genes are 
predicted to code for, for example, surface-exposed proteins. 
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These are cloned and express in Escherichia Coli, purified and used to 
immunized mice. The sera obtained are used to confirm the surface exposure 
of the proteins by ELISA and FACS analysis and tested for the ability to induce 
complement mediated in vitro killing of bacteria. 
This approach permitted to discover novel surface exposed proteins which are 
able to induce bactericidal antibodies. 
 
 
 
 
 
Figure 5. Schematic representation of Reverse Vaccinology approach for the 
identification of new vaccines candidates (Rappuoli, 2001). 
 
1.7.2 Reverse vaccinology and the structural vaccinology approaches for 
Meningococcus B (MenB) 
Group B meningococcus (MenB) represents the first example of a successful 
application of reverse vaccinology.  
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The antigens selected by reverse vaccinology were choosen based on their 
ability to induce broad protection.  
Novartis Vaccines combined five antigens into a multicomponent vaccine, 
named 5CVMB (5 Component Vaccine against MenB), that entered Phase III 
clinical trials in 2008 (35, 36), trusting that this would increase the breadth of 
vaccine coverage and avoid selection of escape mutants. This vaccine, 
formulated with an adjuvant suitable for human use as alum, covers 78% of 
the strains and coverage can be increased to major 95% of the strains by 
using other adjuvants.  
The  major antigen molecule of this universal vaccine against meningococcus 
B is the factor H binding protein (fHbp), a 27-kDa surface exposed lipoprotein 
of Neisseria meningitidis discovered while screening the bacterial genome for 
vaccine candidates. 
1.7.3 Factor H binding protein (fHbp), a new antigen of N.Meningitidis 
Factor H-binding protein (fHbp) is essential for pathogenesis because it allows 
the bacterium to survive and grow in human blood by binding the human 
complement factor H (hfH). 
hfH is one of the most important complement component in the frame of the 
immunity system and allows humans to distinguish between invasive agents 
and self-tissues by coating the latter and avoiding the complement attack. 
One of the most popular strategies among pathogens to avoid complement 
system consists in covering themselves with factor H in order to mimick the 
host surface. fHbp of N. meningitidis is a typical example of this class of 
molecules. 
The protein is expressed by all the pathogenic strains of Neisseria meningitidis 
and can be classified in three distinct sequence variants (37) with levels of 
sequence similarity ranging from 62.8% between variants 1 and 3 to 74.1% 
between variants 1 and 2 and 84.7% between variants 2 and 3 (figure 6). 
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. . . .10 . . . .20 . . . .30 . . . .40 . . . .50
5945    1:VNRTAFCCLSLTAALILTACS.....SGGGGVAADIGAGLADALTAPLDH: 45
m1239   1:VNRTAFCCLSLTTALILTACSSGGGGSGGGGVAADIGTGLADALTAPLDH: 50
mc58    1:VNRTAFCCLSLTTALILTACS.....SGGGGVAADIGAGLADALTAPLDH: 45
 
           . . . .60 . . . .70 . . . .80 . . . .90 . . . 100
5945   46:KDKSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD...SLNTGKLKNDKV: 92
m1239  51:KDKGLKSLTLEDSIPQNGTLTLSAQGAEKTFKAGDKDNSLNTGKLKNDKI:100
mc58   46:KDKGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD...SLNTGKLKNDKV: 92
 
           . . . 110 . . . 120 . . . 130 . . . 140 . . . 150
5945   93:SRFDFIRQIEVDGQLITLESGEFQIYKQDHSAVVALQIEKINNPDKIDSL:142
m1239 101:SRFDFVQKIEVDGQTITLASGEFQIYKQNHSAVVALQIEKINNPDKTDSL:150
mc58   93:SRFDFIRQIEVDGQLITLESGEFQVYKQSHSALTAFQTEQIQDSEHSGKM:142
 
           . . . 160 . . . 170 . . . 180 . . . 190 . . . 200
5945  143:INQRSFLVSGLGGEHTAFNQLP.DGKAEYHGKAFSSDDAGGKLTYTIDFA:191
m1239 151:INQRSFLVSGLGGEHTAFNQLP.GGKAEYHGKAFSSDDPNGRLHYSIDFT:199
mc58  143:VAKRQFRIGDIAGEHTSFDKLPEGGRATYRGTAFGSDDAGGKLTYTIDFA:192
 
           . . . 210 . . . 220 . . . 230 . . . 240 . . . 250
5945  192:AKQGHGKIEHLKTPEQNVELAAAELKADEKSHAVILGDTRYGSEEKGTYH:241
m1239 200:KKQGYGRIEHLKTLEQNVELAAAELKADEKSHAVILGDTRYGSEEKGTYH:249
mc58  193:AKQGNGKIEHLKSPELNVDLAAADIKPDGKRHAVISGSVLYNQAEKGSYS:242
 
           . . . 260 . . . 270 . . . 280 .
5945 242:LALFGDRAQEIAGSATVKIGEKVHEIGIAGKQ:273
m1239 250:LALFGDRAQEIAGSATVKIGEKVHEIGIAGKQ:281
mc58  243:LGIFGGKAQEVAGSAEVKTVNGIRHIGLAAKQ:274
 
 
 
Figure 6. Aminoacidic sequence alignment of variant 1, 2, 3 of fHbp. In white, 
grey and black are indicated  not conserved,  conserved and identical residues 
respectively. 
 
As already mentioned before the structural approach as been applied to MenB 
and through NMR spectroscopy in 2006 the solution structure of the carboxyl 
terminal domain of fHbp (fHbpc) was determined (38). 
The main project of my PhD consisted in the structural study of fHbp full 
length, being the latter the major component of the universal vaccine; the 
structural approach applied to N.Meningitidis allowed to obtain important 
information about this crucial antigen and to subsequentely provide the basis to 
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understand the molecular mechanisms behind the function of this important 
molecule. 
1.8 Steps of the research 
My research was first devote to the study of the interaction between fHbpC and 
MAb502, a bactericidal monoclonal antibody elicited in mice by fHbp, using a 
combination of serological data, NMR measurements and docking calculations.  
The data showed that MAb502 recognizes, within a well-defined area of the 
protein, a conformational epitope, whose identification provides valuable 
information for the rational engineering of fHbp, aimed to create a chimeric 
protein presenting a wider collection of neutralizing epitopes to the host 
immune system (chapter 3). 
After that, the following determination of the solution structure of the full-length 
fHbp variant 1 by NMR spectroscopy, as anticipate before, improved the 
knowledge about the distribution of protective epitopes on the protein surface 
and provided useful indications on the possible localization of the binding site 
of the factor H protein. The protein is composed of two independent domains 
connected by a short link. The structure therefore provides the basis for 
designing improved vaccine molecules (chapter 4). 
The subsequent investigation through NMR measurements of the interaction 
between fHbp and a construct of human factor H comprising domains 5, 6 and 
7 (hfH567) allowed to predict residues involved in the binding with hfH (chapter 
5). 
My study on fHbp proceeded with the investigation on the interaction between 
the protein and the monoclonal antibody JAR4, a mAb that was isolated from a 
mouse immunized with recombinant fHbp in the variant 1 group (39).  
This mAb was not bactericidal with human complement when tested alone (39); 
however, it elicited cooperative, complement mediated bactericidal activity with 
other non-bactericidal mAbs specific for fHbp in the variant 1 or 2 group (40, 
41)  (chapter 6). 
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After that, in order to identify epitopes that are variant-specific, fHbp variant 1 
mutants were performed and, at present, I am studying 10 mutants of the fHbp. 
Then, the determination of the solution structure of other variants of fHbp (in 
my particular case, variant 3) will allowed to proceed on the investigation of the 
interaction with other mAbs. 
 
The aim of the global project is to obtain a vaccine which could be cross-
reactive and immunogenic against the most of meningococcal strains; for this 
reason we are interesting in studying how fHbp interacts with several mAbs, 
which are residues involved in this interaction and how it would possible to 
create a chimeric molecule containing an epitope able to cover the most 
possible strains of Meningococcus; indeed structural vaccinology could 
represent a powerful tool for the rational design or modification of vaccine 
antigens to improve their immunogenicity and safety. 
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2.1 NMR and high-resolution structure determination  
X-ray crystallography and NMR spectroscopy are the two main techniques that 
can provide structures of macromolecules at atomic resolution. Both 
techniques play a key role in structural biology for understanding of molecular 
functions and mechanisms which are involved in several physiological 
processes.  
Whereas X-ray crystallography requires single crystals, NMR measurements 
can be carried out in solution with possibility to adjust conditions, such as 
temperature, pH and salt concentration, to be as close as possible to the 
physiological fluids. Moreover NMR measurements not only provide structural 
data but also can supply information on the internal mobility of proteins on 
various time scales, on protein folding and on intra-, as well as, intermolecular 
interactions. 
In my thesis the latter studies are also supported by molecular docking 
programs, such as HADDOCK (High Ambiguity Driven protein-protein 
DOCKing). 
 
The principles of NMR structure determination can be summarized with 
the following steps: 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation of protein solution 
sample 
NMR Spectroscopy 
Sequence Resonance Assignment 
Calculation of the 3D structure 
Collection of conformational 
constraints 
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The standard protocol includes the preparation of a homogeneous sample of 
the protein solution, the recording and handling of the NMR datasets, and the 
structural interpretation of the NMR data. 
2.1.1 Sample preparation  
The first step to solve the three dimensional structure of biological 
macromolecules is the preparation of the sample, since a highly purified 
protein preparation is required. In fact, an inhomogeneous preparation and/or 
aggregation of the protein may severely compromise the structure 
determination. The first step in every protein NMR study therefore involves 
optimization of the measurement conditions as pH, ionic strength, and 
temperature that can often be adjusted to mimic physiological conditions. The 
macromolecule under study should be stable in the chosen conditions for 
many weeks.  
Proteins with a molecular weight larger than 10 kDa must be isotope enriched 
in 15N and 13C for an efficient structure determination. Triple labelled sample, 
2H, 13C and 15N, is necessary for protein with larger size (more than 30 kDa). 
2.1.2 NMR spectroscopy 
It is not possible to perform the data interpretation on 1D NMR, since biological 
macromolecules contain thousands of resonance lines. 
Moreover, the interpretation of NMR data requires correlations between 
different nuclei, which are implicitly contained in 1D spectra but often difficult to 
extract. Therefore multidimensional NMR spectra are required for proteins 
structural determination. The crucial step in increasing the dimensionality of 
NMR experiments lies in the extension from one to two dimensions. A higher 
dimensional NMR experiment consists of a combination of two-dimensional 
(2D) experiments and extension from a 2D to a n-dimensional (nD) NMR 
experiment consists in the combination of (n-1) two-dimensional experiments 
which contains only one excitation and one detection period but repeats the 
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evolution and mixing times (n-1) times. A typical nD NMR experiment thus 
follows the scheme:  
 
excitation - (evolution - mixing)n–1 – detection 
 
where the bracket repeats (n–1) times. Only during the detection period the 
signal is physically measured and this period is often referred to as the direct 
dimension in contrast to the evolution periods which are referred to as indirect 
dimensions. 
The NMR multidimensional measurements almost always use protons (1H) 
and, depending on the isotope labelling, 13C and/or 15N nuclei. A 3D spectrum 
can for example be obtained by correlating the amide groups with the α-carbon 
nuclei attached to 15N. The chemical shifts of these carbon nuclei are used to 
spread the resonances from the 2D plane into a third dimension. These 3D 
triple resonance NMR experiments are used to correlate backbone resonances 
to corresponding residues in the primary sequence of a protein. 
The proton offers the best sensitivity and for this reason constitutes the 
preferred nucleus for detection of the NMR signal. The other nuclei are usually 
measured during evolution periods of multidimensional NMR experiments and 
their information is transferred to protons for detection. 
Beside 1H NMR, 13C direct detection technique provides a valuable alternative 
to overcome fast relaxation (1). Due to the smaller magnetic moment of the 13C 
nucleus, the transverse relaxation rates on 13C spins are much slower than 1H. 
By exciting 13C spins directly, the signal loss due to the fast relaxation of 1H 
during the magnetization transfer can be reduced. 2D and 3D pulse sequence 
for backbone assignment of 13C direct detection and 13C -13C NOESY type 
experiments are available (2).  
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For small proteins (less than 10k Da), 13C or 15N labelling is not required. In 
this case the assignment strategy makes use of a combination of 2D 
homonuclear 1H NMR experiments such as TOCSY, and NOESY spectra.  
TOCSY-type experiments, where TOCSY stands for Total Correlation 
Spectroscopy, correlate different nuclei via J coupling (3, 4). In proteins which 
are isotope labelled with 15N and 13C J couplings between 1H, 15N and 13C 
allow through-bond correlations across the peptide bond. 
Differently, geometric information, required to determine the structure of 
a protein, are obtained by through-space correlation experiments via nuclear 
Overhauser effect (NOE), the strength of which relies mainly on dipolar 
coupling (5). NOEs connect pairs of hydrogen atoms separated by less than 
about 5 Å. 
Moreover, in the NOESY-experiments, where NOESY stands for NOE 
SpectroscopY (6), the nuclei involved in the NOE correlation can belong to 
amino acid residues that may be far apart along the protein sequence but 
close in space. For molecules with a molecular weight of more than 5 kDa the 
intensity of an NOE is approximately proportional to r-6 and to the molecular 
weight, where r is the distance between the two interacting spins. 
2.1.3 Backbone and side chains Resonance Assignment 
For a good analysis of NMR spectra and to solve the 3D structure, nearly 
complete assignments of signals in the spectra to individual atoms in the 
molecule are required.  
 The application of multidimensional NMR spectroscopy allowed the 
development of general strategies for the assignment of signals in proteins. All 
procedures use the known protein sequence to connect nuclei of amino acid 
residues which are neighbours in the sequence. As mentioned before, for 
unlabelled proteins smaller than 10 kDa the combination of the [1H,1H]-
TOCSY, used for the sequential assignment, with the [1H, 1H]-NOESY 
spectrum allows the assignment of most proton NMR signals to individual 
protons (7). 
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For larger proteins extensive signal overlap prevents complete assignments of 
all 1H signals in proton spectra. This problem can be overcome with 3D NMR 
technique and uniformly 13C and 15N labelled proteins. The resonance 
assignment of single (15N or 13C) labelled proteins using 3D experiments is 
basically an extension of Wüthrich’s strategy which exclusively relies on 
homonuclear 1H NMR experiments. With these methods, systems with 
molecular weights up to approximately 30 kDa can be studied. 
In 13C, 15N-labelled proteins a sequential assignment strategy is based on 
through-bond correlations across the peptide-bond between sequential amino 
acids. This procedure circumvents the use of NOESY spectra already in the 
assignment step. Most of these correlation experiments use the three types of 
nuclei 1H, 15N, 13C and are referred to as triple resonance experiments. 
The 3D triple resonance experiments exclusively correlate the resonances of 
the peptide backbone (HN(i), N(i), Cα(i), Hα(i), Cα(i-1), CO(i) and CO(i-1)). 
Figure 1 shows the spin system of the peptide backbone and indicates the size 
of the coupling constants used for magnetization transfer in double 13C-, 15N-
labelled proteins.  
 
 
Figure 1. Spin system of the peptide backbone and the size of the 1J and 2J 
coupling constants that are used for magnetization transfer in 13C-, 15N-
labelled proteins. 
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The 3D experiments used to identify the backbone resonances are, usually, 
HNCA or HNCACB, HN(CO)CA or HN(CO)CACB, HNCO, HN(CA)CO and 
HNHA (8). The HNCACB for example, correlates each H-15N group with both 
the intra- and the neighbouring inter-residue Cα and and Cβ. These four types 
of connectivities are discriminated using the HN(CO)CACB experiment, in 
which only the inter-residue HN-Cα and Cβ couplings are observed. 
Similar strategy can be used to assign the other resonances in the other triple 
resonance spectra.  
In the case of proteins with a molecular weight larger than 30 kDa, the use of 
TROSY-type experiments is necessary (9). TROSY experiments can reduce 
the signal loss, which is the direct consequence of the slower correlation 
tumbling of large molecules that results in faster relaxation and consequently 
broader lines in the NMR spectrum. 
TROSY uses constructive interference between different relaxation 
mechanisms and works best at the highest available magnetic field strengths 
in the range of 700 to 900 MHz proton resonance frequencies. With TROSY 
the molecular size of proteins accessible for detailed NMR investigations has 
been extended several fold. The TROSY technique benefits a variety of triple 
resonance NMR experiments as the 3D HNCA and HNCOCA (10) and the 
TROSY-based NOESY experiments (11) for the collection of structural 
constraints are also available. 
CRINEPT-TROSY is another recently developed technique for even larger 
proteins. CRINEPT-TROSY can yield a further significant gain in sensitivity for 
molecular sizes above 200kDa (12, 13). The best magnetic field strengths for 
CRINEPT-TROSY are in the range 900-1000MHz proton resonance 
frequencies. 
 
Since the Hα and Cα/β chemical shifts have been assigned, 3D H(C)CH-
TOCSY and (H)CCH-TOCSY (14) experiments are then used to link the side 
chain spin systems to the backbone assignments. These two experiments 
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provide information for the assignment of the side chain protons and of the 
side chain carbons, respectively. 
A complete set of backbone chemical shifts for all Hα, Cα, Cβ and CO 
resonances can be used to predict the secondary structure of the protein (15). 
One technique in particular, the Chemical Shift Index (CSI) (16), has been 
widely used for the quantitative identification and location of secondary 
structure in proteins.  
The method relies on the fact that the chemical shifts of the different nuclei in 
the protein backbone are related both to the type of aminoacid and to the 
nature of the secondary structure they are located in. By comparing the actual 
chemical shift for a nucleus in a specific amino acid with a reference value, it is 
possible to predict in what secondary structure element the nucleus resides.  
Another system for the secondary structure prediction is TALOS (Torsion 
Angle Likelihood Obtained from Shift and sequence similarity) which allowed to 
predict phi and psi backbone torsion angles using a combination of five kinds 
(HA, CA, CB, CO, N) of chemical shift assignments for a given protein 
sequence. 
The method relies on the fact that the phi and psi of the different nuclei in the 
protein backbone are related both to the type of amino acid and to the nature 
of the secondary structure they are located in.  
2.1.4 Collection of conformational constraints 
The NMR data analysis permits to collect geometric conformational information 
in the form of distances and/or torsion angles, which are subsequently used for 
structure calculation. The latter can be performed combining information about 
the covalent structure of the protein, such as the amino acid sequence, bond 
lengths, bond angles, chiralities, and planar groups, as well as by steric 
repulsion between non-bonded atom pairs together with the experimental data. 
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Although a variety of NMR parameters contain structural information, the 
crucial information comes from NOE measurements which provide distance 
information between pairs of protons. 
Supplementary constraints can be derived from through bond 
correlations in the form of dihedral angles (17). Further, CSI and TALOS too 
data provides, as mentioned before, information on the type of secondary 
structure. Such information can be included in a structure calculation by 
restricting the local conformation of a residue to the α- helical or β-sheet region 
of the Ramachandran plot through torsion angle restraints.  
Moreover, hydrogen bonds can be experimentally detected via through-bond 
interactions (18) and they can be useful during structure calculations of larger 
proteins when not enough NOE data are available yet.  
 
Another class of conformational restraints that can be introduced is constituted 
by residual dipolar couplings (RDCs) in the presence of an external orienting 
medium; RDCs give information on angles between covalent bonds and 
globally defined axes in the molecule, namely those of the magnetic 
susceptibility tensor (19, 20). 
 
The intensity of a NOE, i.e. the volume V of the corresponding cross 
peak in a NOESY spectrum (21, 22), is related to the distance r between the 
two interacting spins by 
V=<r-6>f (τc)                                                       (1) 
where averaging r indicates that in molecules with inherent flexibility the 
distance r may vary and thus has to be averaged appropriately. This volume is 
also dependent on the function f(τc) that includes effects of global and internal 
motions of the molecule. 
 
NOEs are usually treated as upper interatomic distance rather than as precise 
distance restraints. Adding the information on the distance between pairs of 
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protons and their position in the polypeptide sequence allows construction of 
possible arrangements in which all distance constraints are fulfilled. 
Vicinal scalar coupling constants, 3J, can also be used for torsion angle 
prediction, according to Karplus relations (23): 
 
3J(θ) = Acos2 θ + Bcosθ +C                                             (2) 
 
where θ is the torsion angle; A, B and C are Karplus constants depending on 
the type of the torsion angle. 3J HNHa coupling constants are obtained from 
the ratio between the intensity of the diagonal peak and that of the cross-peak 
of the HNHA map. 
 
Through the analysis of the HNHB spectrum the 3JHNHβ coupling constants (χ 
torsion angles) can be derived. The process of defining useful conformational 
constraints on the basis of J coupling constants usually requires the translation 
of these quantities into molecular-geometry related dihedral-angle values.  
 
Using NMR constrains, calculation programs fold a random generated 3D 
structure, in order to maximize the agreement between the structure and the 
structural constrains. A NMR structure is represented by a family of 
conformers which are in good agreement with the structural constrains 
imposed. The precision of the structure is measured by the root-mean-square-
deviation (RMSD) of the coordinates of the protein atoms for each conformer 
of the family from the mean structure and the accuracy of the structure is 
measured by an average target function of the family; the latter measures the 
agreement between the structure and the given set of constrains. 
2.1.5 Structure calculation, refinement and validation 
Starting from chemical shifts and NOESY spectra all the calculation works 
have been done with the programs ATNOS-CANDID coupled with CYANA-2.0 
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by using torsion angle dynamics algorithm. In this algorithm, the molecular 
dynamics simulation uses torsion angles as degree of freedom, while bond 
lengths, angles, and backbone peptide plane angles are fixed. 
In particular, ATNOS/CANDID program, based on the backbone and side-
chains assignment, allow to obtain the automated NOESY peak picking 
(ATNOS) and the automated NOE assignment (CANDID). 
 
During the integration time steps, the best conformation was searched by 
minimized the deviation between the constrains and obtained conformations. 
Compared with other algorithms, torsion angle dynamics provides at present 
the most efficient way to calculate NMR structures. 
 
At the end of the structure calculation, an important question is if the structure 
calculation was “successful”. There are two important features, i) whether the 
calculated structures fulfill the given restraints, ii) whether the calculations are 
converged. The first feature could be described by statistical report of the 
target function. In each calculation, 20 or 30 conformers, among 200 or 350 
conformers, with lowest final target functions were chosen to represent the 
solution structures. The average values of target function of the represent 
structures should be smaller than 1Å2 and each single violation should be 
smaller than 0.3 Å2. The second feature was judged by RMSD between these 
models. Only the family structure with backbone RMSD values close or less 
than 1 Å will be considered as “good”. 
The “good” structures obtained from torsion angle dynamics finally will be 
refined in AMBER program (24). In the final refinement, force field parameters 
are also considered. 
The refinement in explicit water box after the refinement in vacuum make the 
structure qualities further improved. 
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The solved structures could be flawed or present a wrong fold, even if RMSD 
and target function values are accepted. The defect could be induced by only a 
few wrong assigned NOEs or other local constraints. The validation package 
provides a tool to understand the quality of the structures. In this thesis, 
programs PROCHEK_NMR, WHATIF and QUEEN are used for judging the 
structure quality. The solution structures will be accepted if more than 90% 
residues fall into the allowed region of Ramachandran plot and less than 1% 
residues in the disallowed region. 
PROCHEK_NMR provides a detailed check on the stereochemistry of a 
protein structure, while WHATIF (25) try to assess the quality of a structure 
primarily by checking whether a number of different parameters are in 
agreement with their values in databases derived from high-resolution X-ray 
structures. 
QUEEN (QUantitative Evaluation of Experimental Nmr restraints) is a method 
which describes the quantitative evaluation of experimental NMR restraints. 
This method successfully identifies the crucial restraints in a structure 
determination: those restraints that are both important and unique. 
2.2 Mapping Protein-Protein Interactions in Solution by NMR 
Spectroscopy 
A large majority of the functional processes in the cell occur through weak 
transient interactions among proteins (interactome). Unfortunately, the 
characterization at the atomic level of these weak interactions is difficult, due 
to their dynamic nature. NMR is a very well suited technique as it allows us to 
characterize also dynamical and kinetic properties. The available NMR 
methods to this end are reviewed and illustrated with applications from the 
recent biochemical literature: intermolecular NOEs, cross-saturation, chemical 
shift perturbation, dynamics and exchange perturbation, paramagnetic 
methods and dipolar orientation. 
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Most of these methods are now routinely applied for complexes with total 
molecular mass of 60 kDa and can likely be applied to systems up to 1000 
kDa.  
 
 The study of protein-protein interactions by NMR appears to be one of 
the most important application; this evolution became possible because of 
better NMR equipment, development of more efficient isotopic labelling 
schemes, especially perdeuteration (26) and the advent of TROSY (9) and 
CRINEPT-TROSY (12, 13) 
2.2.1 Chemical Shift Perturbation Mapping 
 Chemical shift perturbation is the most widely used NMR method to 
map protein-protein interfaces. The 15N-1H HSQC spectrum of protein “A” is 
monitored when the unlabelled interaction partner (protein “B”) is titrated in, 
and the perturbations of the chemical shifts are recorded. The approach 
requires that sequence-specific assignments have been determined for protein 
A at least in its free state. 
 The interaction causes environmental changes on the protein interfaces 
and, hence, affect the chemical shifts of the nuclei in this area. In some cases 
the entire protein may change conformation, and all chemical shifts may be 
affected; then the chemical shift perturbation fails as a mapping device but is 
an excellent indicator of allosteric processes (27, 28). 
 Shift perturbation measurements just yield the locations of the interfaces 
on the individual binding partners, but not how the partners interact at atomic 
level. One approach may be to combine the NMR shift mapping experiments 
with computational docking programs (29). 
2.2.2 Titration with NMR 
 NMR titration allows, in addition to the mapping of the interface, a good 
estimation of the affinity, stoichiometry, and specificity of binding as well as the 
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kinetics of binding. How the chemical shifts of the labelled protein change 
during the titration is determined by the kinetics of the interaction.  
If the complex dissociation is very fast, there is, even during the titration, only a 
single set of resonances whose chemical shifts are the fractionally weighted 
average of the free and bound chemical shifts. Here the resonances of nuclei 
at the interface move in a continuous way during the titration. This regime is 
referred to as fast chemical exchange and is often observed for weaker 
interactions. 
If the complex dissociation is very slow, one observes one set of resonances 
for the free protein and one set for the bound protein. During the titration, the 
“free set” will disappear and will be replaced by the bound set. This regime is 
referred to as slow chemical exchange. In slow exchange one does not 
automatically know to which new location the resonance has moved, unless 
one carries out an 
independent assignment procedure for the bound state. 
In the intermediate chemical exchange case, the frequencies of the changing 
resonances become poorly defined, and extensive kinetic broadening sets in 
(30). A rule of thumb is that interactions with Kd <10 µM are slow exchange 
and intermediate/fast exchange otherwise. 
 2.3 Internal mobility in proteins 
The study of the protein mobility is particular important to understand biological 
and chemical phenomena for the recognized importance of protein internal 
motions in biological processes. Macromolecular functions are often 
associated to energetic transition, which are intimately connected with 
structural changes and molecular flexibility.  
The measurement of 15N relaxation rates in isotopically enriched 
proteins is particularly useful for obtaining dynamics information since the 
relaxation of this nucleus is governed predominantly by the dipolar interaction 
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with directly bound proton and by the chemical shift anisotropy (CSA) 
mechanism.  
In an 15N relaxation experiment, one creates non-equilibrium spin order and 
records how this relaxes back to equilibrium. At equilibrium, the 15N 
magnetization is aligned along the external field, and this alignment can be 
changed by radio frequency pulses. The magnetization will relax back to 
equilibrium along the direction of the magnetic filed with a constant time called 
longitudinal relaxation time T1. When outside equilibrium the magnetization 
can have also a component perpendicular to the external magnetic field. The 
time constant for this spin component to return to equilibrium is called 
transverse relaxation time, T2. A third source of relaxation parameter is the 
heteronuclear NOE. This is measured by saturating the proton (1H) signal and 
observing changes in the 15N signal intensities. 
The relaxation parameters are related to the spectral density function, of the 
1H-15N bond vector by the following equations (31, 32): 
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in which d=(µ0hγNγH/8pir3NH) and c=ωN∆N/√3. Rex is a term introduced to account 
for microsecond to millisecond conformational exchange contributions to R2.  
The dynamic information contained in the relaxation rates are 
represented by the values of the spectral density function, J(ω), at several 
frequencies. The descriptions of the dynamics requires therefore the 
identification of a suitable model for the spectral density function, which must 
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be consistent with the experimental relaxation rates. The spectral density is 
often expressed in terms of global tumbling parameters, and of local motional 
parameters.  
 
2.3.1 Data Analysis 
2.3.1a Spectra Density Mapping  
The spectral density mapping approach was developed by Peng and 
Wagner in 1992 (33). It makes use of six different relaxation parameters, which 
are used to map the spectral density function. These parameters are: 1) the 
longitudinal 15N relaxation rate, R1, 2) the transverse 15N relaxation rate, R2, 3) 
the 1H→15N heteronuclear NOE, 4) the relaxation rate of longitudinal two-spin 
order RNH(2HzNz), 5) the relaxation rate of anti-phase 15N coherence 
RNH(2HzNx,y) and 6) longitudinal relaxation of the amide protons.  
The method of spectral density mapping does not require any 
assumption regarding the form of the spectral density functions. Values of the 
spectral density functions of 1H-15N vectors are directly sampled at several 
relevant frequencies (e.g. 0, ωH-ωN, ωH+ωN, ωH, ωN).  
Drawbacks in this method reside in the fact that the three measurable 
relaxation parameters, R1, R2 and heteronuclear NOE, are insufficient to 
determine uniquely the values of the spectral density function at the five 
frequencies in equations (1) to (3) and that anomalous behaviour can be 
expected for the spectral densities at the three highest frequencies (33). These 
problems can be overcome by a more recent approach called reduced spectral 
density mapping, in which the values of the spectral density function at ωH-ωN, 
ωH+ωN and ωH frequencies can be combined in a average spectral density 
<J(ωH)> (24, 25). A comparison of J(ω) measured at high and low frequencies 
provides a quantitative measure of the breadth of the frequency distribution 
accessed through the spatial fluctuations of the bond and the overall tumbling 
of the molecule. 
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2.2.1b Model Free Approach 
A different method, called Model Free approach, has been introduced 
by Lipari and Szabo (34). This model assumes that the overall rotation of the 
molecule can be described  by a single correlation time (isotropic motion) and 
that this overall motion and the internal motions are independent. Then the 
total correlation function can be factored as:  
C(t)= CO(t)× CI(t) (6)
  
Where C(t) is the total correlation function, CO(t) is the correlation function 
characterizing  the overall rotation and CI(t) is the correlation function 
characterizing the internal motions. 
As a consequence, the global spectral density function can be 
expressed as a weighted sum of Lorentzian functions. This is correct 
rigorously for isotropic rotational diffusion and approximately for anisotropic 
rotational diffusion.  
The Lipari and Szabo formalism employs a minimum number of 
parameters to describe the overall isotropic tumbling motion of a 
macromolecule and the internal motions of the 15N-1H bond vector. The central 
equation in the Model Free Approach is:  
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 where τm is the correlation time as a result of the isotropic tumbling motion of 
the entire molecule. The effective correlation time resulting from internal 
motions is described by τe, where τ -1 = τm-1 + τe-1. The order parameter S2 
describes the degree of spatial restriction of the internal motion of the 1H-15N 
bond vector. It satisfies the inequality 0 ≤ S ≥ 1 and lower values indicate 
larger amplitudes of internal motions. As a consequence, for a nucleus rotating 
Methodological Aspects 
_____________________________________________________________________ 
 45 
as a whole with the molecule, all contributions to the spectral density function 
derive from the overall tumbling; alternatively, extra contributions will be 
described by other motions with correlation times faster than the overall 
tumbling. 
An extended form of the model-free spectral density function has been 
developed by Clore and coworkers (35) to describe internal motions that take 
place on two distinct time scales, differing by at least an order of magnitude.  
2.2.3 The contribution to relaxation of exchange processes  
The presence of exchange processes occurring in the micro-millisecond 
time scale produces dephasing of magnetization and contributes to make the 
transverse relaxation time shorter.  
A method to obtain a detailed analysis of exchange contribution is the 
measurement of R2 rates as a function of the refocusing times 
τCPMG(=1/(2νCPMG), where νCPMG is the frequency of repetition of 180° pulses 
during the Carr-Purcell-Meiboom-Gill (CPMG) sequence (36). 
The contribution of the exchange processes (Rex) to the transverse relaxation 
rate can be expressed as follow (37): 
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where ξ = ( kex2 – 4pApBδω2)1/2 , kex = 1/τex and ν eff(s-1) =  )(2
1
CPMGτpi +T
 
pA and pB are the populations of the sites A and B in a two-site exchange 
process, δω is the difference of Larmor frequencies between the sites and τex 
is the time constant for the exchange process.  
2.4 Molecular Docking for the study of protein-protein interaction 
Molecular docking have been investigated through the program HADDOCK 2.0 
(38). 
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In the latter the docking process is driven by ambiguous interaction restraints 
(AIRs), which are ambiguous distances between all solvent exposed residues 
involved in the interaction. HADDOCK protocol defines active and passive 
residues. 
The active residues are all residues showing a significant chemical shift 
perturbation after the formation of the complex, with a solvent accessibility 
usually > 50%; the passive residues are the residues which are surface 
neighbors of the active and have a solvent accessibility usually  > 50%. 
Solvent accessibility has been calculated with the program NACCESS (39). 
In this work of thesis I considered a solvent accessibility > 40%. 
2.4.1 Docking Protocol 
 The docking protocol consists of three consecutive steps: 
a) rigid body minimization driven by interaction restraints (it0), in which 
1000 structures of the complex have been generated; 
     b)   the best 200 structures in terms of total intermolecular energy were 
further submitted to the semiflexible simulated annealing in which side-chains 
and backbone atoms of the interface residues are allowed to move (it1); 
b) final refinement in Cartesian space in a explicit solvent (water). 
Finally the 200 structures obtained are clustered using a threshold of 7.5 Å of 
RMSD among the structure of the cluster.  
 
Clusters containing 5 structures were considered and I performed a detailed 
analysis on the first two clusters which showed a lower HADDOCK score value 
(HADDOCK score: 1Evdw+0.2Eelc+0.1Edist+1Esolv, where the four terms are 
respectively: Van der Walls energy, electrostatic energy, distance restrains 
energy and desolvation energy). 
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Neisseria meningitidis causes severe, often fatal
septicemia and meningitis. Polysaccharide-based
vaccines are available in preventing diseases caused
by pathogenic serogroups A, C, Y, and W-135 in
older children and adults. The development of a safe
and effective vaccine against serogroup B has been,
on the contrary, hampered for a long time because of
the poor immunogenicity and cross-reactivity ofresses:
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MD, molecular
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ublished by Elsevier Ltd.type B capsular polysaccharide with sialylated pro-
teins of human tissues.
So far, outer membrane-based vaccines such as the
New Zealand MeNZB1 and the Cuban VA-MEN-
GOC-BC® have been licensed against serogroup B
meningococcus for local use.2 Recently, a universal
protein-based vaccine3 containing five novel anti-
gens discovered by reverse vaccinology, a process
that involves whole bacterial genome screening, has
been proposed.4 One of these antigens is a mem-
brane-anchored lipoprotein of 274 amino acids
known as factor H binding protein (fHbp), also
termed GNA1870 and lipoprotein 2086.5,6 In addi-
tion to inducing bactericidal antibodies in mice, this
protein is indeed able to bind human factor H, a
negative regulator of the alternative complement
pathway. It has been proposed that, in addition to
triggering the classical complement pathway, which
in turn results in bacterial killing, antibody binding
to fHbp could enhance the protective power of the
immune response by inhibiting the bacterium ability
to down-regulate the alternative cascade.7 All these
observations increase the relevance of fHbp in
Table 1. Summary ofWB, FACS reactivity, andbactericidal
titers (SBA) of MAb502 and anti-fHbpMC58 antibodies
against strains carrying different variant 1 fHbp alleles
Strain
Polyclonal serum MAb502
WB FACS SBA WB FACS SBA
MC58 + +++ 16,384 + +++ 256
M4030 + ++ 2048 + + b4
M01-240149 + +++ 2048 + + b16
F6124 + ++ 1024 + + b4
LPN17592 + + 512 + + b4
M01-240345 + ++ 512 + + b4
NZ98/254 + ++ 64 − − b4
M2197 + +++ 512 − − b4
M6190 + ++ 128 − − b4
M2937 + ++ 1024 − − b16
SBA values are expressed as serum dilutions resulting in 50%
decrease of bacterial CFUs per milliliter after a 60-min incubation
of bacteria with the reaction mixture compared with the control
CFUs per milliliter at time zero.
98 A Protective Epitope of the Antigen fHbpvaccine efficacy and stimulate interest in a detailed
knowledge of its antigenic profile.
Sequence analysis on a panel of 71 clinical isolates
of N. meningitidis showed that, while the 120 N-
terminal amino acids of the protein are well con-
served, the last 154 C-terminal residues show remar-
kable diversity. The sequence variability correlated
with antigenic variation as polyclonal sera obtained
immunizing with recombinant forms of the protein
were protective versus strains carrying closely
related variants but ineffective against those having
more distant alleles.5
The nature and distribution of protective fHbp
epitopes have been investigated in more detail for
the protein encoded by the pathogenic strain MC58.
It has been demonstrated that the 154 C-terminal
residues of the protein contain most of the protective
epitopes, with this domain being almost as good as
the whole protein in inducing a protective immune
response.8 Moreover, the C-terminal portion of the
protein contains residues targeted by bactericidal
monoclonal antibodies, such as Arg204,8 Glu146,
Gly147, Gly148, and Arg149.9
The solution structure of such C-terminal immu-
nodominant domain of fHbp (fHbpC) has been
determined by nuclear magnetic resonance (NMR)
spectroscopy. This part of the protein forms an eight-
stranded β-barrel whose strands are connected by
loops of variable lengths. The barrel is preceded by a
short α-helix and by a flexible N-terminal tail.10
Sequence alignments of fHbp alleles representa-
tive of the meningococcal population diversity
showed that variable residues were not exclusively
located in correspondence of loops, as expected for a
domain embedded into the outer membrane, but
were spread on the entire surface of theβ-barrel. This
profile of variability, together with the solvent expo-
sure of hydrophilic residues and the observation that
aromatic and hydrophobic residues are buried into
the protein interior, suggested that the β-barrel is
fully exposed on the bacterium surface and acces-
sible to the immune system. The only exception
could be represented by a hydrophobic patch pre-
sent on one side of the β-barrel, which might repre-
sent a contact area to the outermembrane or to theN-
terminal domain of the protein, in any case shielded
to the immune system. The NMR structure also
showed that amino acids previously identified as
targets of protective monoclonal antibodies8,9 clus-
tered within a restricted area opposite to the
hydrophobic patch.
In this study, we investigated the interaction
between fHbpC and MAb502, a bactericidal mono-
clonal antibody elicited in mice by fHbp, using a
combination of serological data, NMRmeasurements,
and docking calculation. Residues forming the bacter-
icidal epitope of fHbpC have been mapped by NMR
titrations with the antigen binding fragment (FAb) of
MAb502 (FAb502). The putative complex between
fHbpC and the hypervariable fragment of FAb502
(Fv502) has been generated by molecular docking.
The data show that MAb502 recognizes a confor-
mational epitope within a well-defined area of theimmunodominant C-terminal domain of fHbp. The
identification of the MAb502 epitope provides
valuable information for the rational engineering of
fHbp, aimed to create a chimeric protein presenting a
wider collection of neutralizing epitopes to the host
immune system.Results
Western blot analysis
To test the binding of MAb502 to fHbp produced
by natural isolates representative of the diverse
meningococcal population, we selected 10 strains,
including MC58, each of them carrying nonredun-
dant fHbp sequences. The anti-MC58 fHbp poly-
clonal serum recognized the protein in Western blot
(WB) on the cell extracts of all the strains tested, and
fluorescence-assisted cell sorting (FACS) experi-
ments confirmed the presence of the protein on the
bacterial cell surface. As expected, the polyclonal
serum elicited by the recombinant protein of MC58
was also able to induce complement-mediated kill-
ing of all strains. On the other hand, MAb502 was
able to recognize fHbp in 6 of 10 strains in WB and
FACS experiments and had a strong bactericidal
activity only against MC58 (Table 1).
Hints on residues involved in the formation of the
MAb502 epitope were searched by analyzing the
sequence differences between the fHbp protein
produced by MC58 strain and that of the other
clinical isolates. Sequence alignment allowed classi-
fying in two groups the amino acid positions
variable between the fHbpC of MC58 and the other
alleles. The first one contained amino acids varying
between MC58 and WB-positive as well as WB-
negative strains (shown in blue in Fig. 1). These
amino acids in MC58 corresponded to Phe109,
Ile114, His119, Glu146, Arg149, Gly163, Ala174,
Fig. 1. Multiple sequence alignment of fHbpC. Amino acids predicted relevant for MAb502 recognition are shown in
red, while predicted dispensable residues are shown in blue. The second column (WB) subdivides strains recognized (+)
or not (−) by MAb502 in WB.
99A Protective Epitope of the Antigen fHbpAsn178, Asp192, Ala195, Ala196, Asp197, Gly202,
Ala217, Lys230, Lys241, Val243, and Arg247. As the
variability of these residues did not impact the WB
recognition by MAb502, we classified their relative
positions as dispensable.
The second group (red positions in Fig. 1) con-
tained residues varying with respect to MC58 only
in WB-negative strains. These amino acids are
Ser117, Gly121, Gln128, Arg130, Pro145, Gly147,
Gly148, Thr167, and Arg204. Among these, Ser117,Gly121, and Gln128 are located in the N-terminal
flexible tail of fHbpC, making it difficult to speculate
on their role in epitope formation. With the excep-
tion of Thr167, all the other residues of this second
group cluster on the same region on the β-barrel
(Fig. 2a).
As already pointed out,6 the Arg204→His sub-
stitution was the sole difference observed consis-
tently in all the WB-negative strains. The relevance
of this position for MAb502 binding was confirmed
Fig. 2. Residues of fHbp that form theMAb502 epitope. (a) Spatial distribution of amino acids predicted as relevant (red
surface) or accessory (blue surface) for MAb502 binding onto the β-barrel domain of fHbp. (b) Amino acids whose NMR
signals were perturbed upon the addition of FAb502 to the NMR sample. van der Waals volumes are reported for surface-
exposed amino acids; buried residues are marked by solid spheres in correspondence to their backbone nitrogen atoms.
Fig. 3. WB of purified recombinant fHbp from MC58
and related mutants carried out by using the polyclonal
antisera (left) orMAb502 (right). Lane 1, fHbp; lane 2, fHbp
Asn178→His; lane 3, fHbp Gly202→Lys; lane 4, fHbp
Asn178→His–Gly202→Lys; lane 5, fHbp Arg204→His.
“M” indicates molecular weight marker.
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fHbp from MC58. When the Arg204 was changed
to histidine, MAb502 was unable to recognize the
protein. In close proximity to Arg204 were located
three amino acids variable only in WB-negative
strains, namely, Pro145, Gly147, and Gly148. On
the basis of this observation, we predicted that the
key residues of epitope recognized by MAb502
were Arg204 together with Pro145, Gly147, and
Gly148.
In order to verify the assumption that residues
classified as dispensable in Fig. 1 have a minor or no
effect on MAb502 binding, we tested by WB the
effects of Gly202→Lys and Asn178→His substitu-
tions. Both mutations, as expected, did not impair
the protein recognition by MAb502 in WB (Fig. 3).
However, because of the absence of bactericidal
activity of MAb502 against all the strains except
MC58, we could not exclude a priori the contribution
by some of these dispensable residues in determin-
ing antibody binding affinity. For this reason, we
speculated that an additional contribution to the
fHbp affinity for MAb502 could be given by the side
chains of Glu146, Arg149, Ala174, and Lys230, loca-
ted within the proximity of the residues predicted as
crucial for epitope formation.
NMR mapping of the FAb502–fHbpC interaction
The predictions on fHbp residues interacting with
MAb502 were tested through NMR spectroscopy, by
analyzing the perturbations caused in the 1H–15Nheteronuclear single-quantum coherence (HSQC)
spectrum of fHbpC upon addition of the FAb
(FAb502). Addition of FAb502 to 15N-labeled fHbpC
caused the progressive reduction in intensity of NH
cross-peaks in the 1H–15NHSQC spectra, which com-
pletely disappeared at the 1:1 ratio (Fig. 4a). The only
exception was represented by residues 100–136
Fig. 4. Interaction of fHbpC with FAb502. (a) 1H–15NHSQC spectrum showing fHbpC (red) superimposed with fHbpC
in the presence of one equivalent of FAb502 (blue). Labels of residues 100–136 belonging to the N-terminal tail are
underlined. (b) 1H–15N HSQC spectrum of fHbpC (red) superimposed with the CRINEPT spectrum acquired on the
fHbpC–FAb502 1:1 mixture (blue). Only amino acids of fHbpC whose amide signals experience chemical shift changes
upon the addition of FAb502 are labeled. Among the latter, only the labels of the ones that are solvent exposed are
underlined. For the unstructured N-terminal tail, both multiplet components are observed in the CRINEPT spectrum.
101A Protective Epitope of the Antigen fHbpbelonging to the N-terminal tail, whichmaintain their
full intensity. Disappearance of the protein backbone
NHs in the HSQC spectra is a consequence of the
formation of the antibody–protein complex, charac-
terized by a high molecular mass (∼70 kDa). The
progressive disappearance of fHbpC signals upon
addition of FAb502 and the absence of any signal
shifting suggested that the complex exchanges with
the free proteins at rates slower than the chemical shift
differences between the two forms (i.e., in the range of
milliseconds). The high mobile N-terminal tail, which
reorients faster than the overall tumbling rate offHbpC, maintained this property in the complex. This
behavior indicated that it was not involved in the
interaction with FAb2502. Similar chemical shift
values for the N-terminal region in fHbpC and the
fHbpC–FAb502 complex also indicated that no
significant conformational change occurred in this
region. When cross-correlated relaxation-enhanced
polarization transfer (CRINEPT) NMR experiments,
which are suitable for high-molecular-weight sys-
tems, were performed, the majority of the NH cross-
peaks reappeared (Fig. 4b). The residues of fHbpC,
which experienced different chemical shifts upon
Table 2. Amino acids of fHbpC whose amide signals
experience chemical shift changes upon the addition of
FAb502
Exposurea Residue
Buried His138, Thr139, Ser140, Leu144 Ala150, Leu166,
Ala174, Lys175, Gln176, Gly177, Asn178, Gly179,
Ala196, Ile198, His205, Gly210, Ser211, Val212,
Leu224, Gly225, Ile226, Gly228, Glu233
Exposed Phe141, Lys143, Gly148, Arg149 Lys199, Lys203,
Arg204, Ala206, Val207, Phe227, Ala238
a As it results from the solvent accessibility calculated with the
program NACCESS.11
Table 3. Statistics on the clusters of the structural models
of the fHbpC–Fv502 complex obtained through docking
calculations
Cluster 1a(best five) Cluster 2 (best five)
HADDOCK scoreb −134 (4) −133 (11)
RMSD (Å)c 1.87 (1.23) 0.76 (0.38)
BSA (Å2)d 2062 (123) 2097 (42)
AIR viole 11.0 (0.9) 12.00 (1.3)
Cluster 1 (all) Cluster 2 (all)
HADDOCK score −104 (23) −87 (25)
RMSD (Å) 3.1 (1.0) 3.4 (2.1)
BSA (Å2) 1915 (135) 1851 (146)
AIR viol 12.4 (1.6) 14.8 (2.2)
The two clusters of solutions contained 35 and 69 structures,
respectively. Averages (standard deviations are reported in
parentheses) were calculated over the best five model structures
and over all the structural models for each of the two clusters of
solutions.
a Cluster rank according to the HADDOCK score.
b HADDOCK score defined as the weighted sum of different
energetic terms: score=(1 Evdw+0.2 Eelc+0.1 Edist+1 Esolv), where
the four terms are van der Waals energy, electrostatic energy,
distance restraint energy, and desolvation energy, respectively.
c Backbone RMSD from the lowest HADDOCK score structure
in each cluster.
d Buried surface area.
e Average number of AIR violations for each cluster.
102 A Protective Epitope of the Antigen fHbpaddition of FAb502, are shown in Fig. 2b and listed in
Table 2. They cluster in one region of fHbpC and
include Arg204, the residue essential for binding to
the antibody,8 as well as Gly148, Arg149, and Ala174.
In addition, spectral perturbations were observed
also for other NH cross-peaks of the surface-exposed
residues, namely, Phe141, Lys143, Lys199, Lys203,
Ala206, Val207, Phe227, Gly228, and Glu233 (Fig. 2b).
Computer modeling of the fHbpC–Fv502
complex
Molecular docking is a computational metho-
dology that uses the known structures of the compo-
nents of a complex to generate a model for the
complex. Docking approaches are becoming increas-
ingly popular for investigating intermolecular com-
plexeswhose structures cannot be studied by classical
structural methods.12,13 They have been applied to a
variety of protein–protein complexes,14,15 including
antibody–antigen complexes.16
To model the structure of the complex between
fHbpC and the hypervariable FAb of MAb502
(Fv502), we performed docking calculations using
as input the NMR structure of fHbpC and a com-
puter homology model of Fv502.
NMR data were used to derive the interaction
restraints on fHbpC. In the absence of any experi-
mental indication on Fv502 residues actually con-
tacting the antigen, all the surface-exposed amino
acids within the six hypervariable loops of the Fv
fragment were used as restraints (Table S1).
As a consequence of the wide interaction surface
defined on Fv502, more than one model of the com-
plexwas obtained, and the sameportion of the fHbpC
β-barrel was involved in the interaction with Fv502
in all of them. From the analysis of the energetic and
scoring functions, it appeared that, essentially, only
two clusters are meaningful. These two lowest-
energy clusters experienced far much better scoring
functionswith respect to the others, larger interaction
surfaces, and a much lower average number of
ambiguous restraints, which indicate better agree-
ment with the experimental data (Table S2). There-
fore, we performed a detailed analysis only on these
two clusters (Table 3). The lowest-energy complex for
each of the two clusters is shown in Fig. 5.
The list of fHbp residues contacting Fv502 in each
structural model is given in Table 4, and a summaryof the intermolecular interactions calculated over the
best five structures of each cluster is reported in
Table S4.
Even if the reciprocal orientations of the molecules
are different, the two clusters showed some common
features, such as the involvement of Arg204 of
fHbpC. In particular, in the first model, hydrogen
bonds were present between the side chain of
Arg204 and the carbonyl oxygen of residues
Thr158 and Ser159 of Fv502. In the second model,
the side chain of Arg204 interacted with the same
region of Fv502, forming indeed a salt bridge not
only with Asp70 but also with Asp124, both of
which are located in the Fv heavy chain (FvH) of
Fv502 (Fig. 5). Another region of interaction present
in both clusters involves residues Phe227–Lys230,
located in the loop between β-strands 6 and 7 of
fHbpC and residues Tyr71–Asp76 of FvH502.
The two structural models of the complex differed,
on the other hand, in the mode of involvement of the
stretchGlu146–Arg149. Hydrogen bonds are present
in the structural models of the first cluster between
the backbone of Gly146 and Arg149 of fHbpC and
the side chains of Tyr51 and His49 of Fv light chain
(FvL) 502. These interactions are absent in the second
cluster, being the stretch Gly147–Arg149 completely
exposed to the solvent (Fig. 4).
MAb502 does not inhibit the fHbp binding to fH
In order to investigate if MAb505 could interfere
with the fH–fHbp interaction, we evaluated by
FACS the ability of human factor H to bind
meningococcal cell surface after preincubation with
two monoclonal antibodies, namely, MAb502 and
JAR5. The latter antibody was previously shown to
cause complete inhibition of fH binding.17 Results
Fig. 5. Structural models of fHbpC–Fv502 complex generated by molecular docking. Lowest HADDOCK score
structure of cluster 1 (top) and that of cluster 2 (bottom) are represented. fHbp is shown in blue, while Fv502 chains are
shown in gold (FvH) and red (FvL). Key residues involved in the intermolecular interactions are shown as solid (fHbpC)
and dotted (Fv502) surfaces.
103A Protective Epitope of the Antigen fHbpare summarized in Fig. 6. While the presence of
JAR5 led to the disappearance of the fluorescence
peak diagnostic of fH binding (Fig. 6a), cells pre-
incubated with MAb502 were still able to retain
factor H on their surface (Fig. 6b). When the sameexperiment was repeated with the MC58 isogenic
mutant lacking the fHbp gene, no difference in the
FACS profile was observed (data not shown). These
data suggested that the fH binding site does not
overlap with the MAb502 epitope.
Fig. 6. Effects of MAb502 on fH binding. FACS profile
of meningococcal cells in the absence (black) and in the
presence (red) of human factor H preincubated with (a)
JAR5, (b) MAb502, (c) mice polyclonal serum elicited
against recombinant fHbp, and (d) PBS buffer.
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Detailed knowledge of epitopes recognized by
protective antibodies is necessary for understanding
the molecular mechanisms responsible for effective
immune response. In addition, epitope mapping of
bactericidal monoclonal antibodies provides a
powerful tool to identify a priori bacterial strains
carrying susceptible antigens. For these reasons, we
undertook the characterization of the epitope recog-
nized by MAb502 raised against fHbp, a powerful
antigen of N. meningitidis.
The present results, obtained from the analysis of
immunological data, NMR mapping, and molecu-
lar docking carried out on fHbp protein in the
presence of MAb502, unequivocally demonstrate
that the fHbp contact area with the antibody is
formed by three independent loops plus the N-
terminal α-helix of the C-terminal domain fHbpC.
In particular, they evidenced the conformational
nature of the MAb502 epitope and confirmed the
key role of Arg204, as well the minor role of
residues Glu146–Arg149.
The reactivity of MAb502 against a panel of
meningococcal strains carrying different alleles of
fHbp provided a first indication of which residues
are more likely involved in epitope formation. FACS
analysis and bactericidal activity of the polyclonal
serum anti-fHbp showed that all the strains analyzed
expressed and exported fHbp on their surface. We
therefore assumed that differences in amino acid
sequences could be interpreted as a major factor
influencing the recognition. Consequently, we pre-
sumed that the MAb502 epitope could potentially
contain all the amino acids that varied in WB-
negative alleles. However, it should be considered
that variability not necessarily implies involvementTable 4. fHbp residues forming the MAb502 epitope
Predicted NMR Cluster 1 Cluster 2
Phe141 Phe141 Phe141
Lys143 Lys143 Lys143
Pro145 a Pro145
Glu146 b Glu146 Glu146
Gly147 b Gly147
Gly148 Gly148 Gly148
Arg149 Arg149 Arg149
Ala174 Ala174
Lys199 Lys199
Lys203 Lys203
Arg204 Arg204 Arg204 Arg204
Ala206
Val207
Phe227 Phe227 Phe227
Gly228 Gly228 Gly228
Lys230 b Lys230 Lys230
Glu233 Glu233 Glu233
Predicted=predicted by sequence alignment. NMR=deduced by
NMR experiments. Cluster 1 and Cluster 2=identified in the
docking complexes.
a Proline residue has no amide proton.
b These residues have not been reported due to spectral overlap
of their backbone amides or as they have a chemical shift
perturbation lower than 0.03 ppm.in the epitope and that not all the differences
observed in WB-negative alleles could equally con-
tribute to the MAb502 recognition. In previous
work, we already indicated Arg204 as a necessary
residue for MAb502 recognition.8 The three-dimen-
sional structure of fHbpC permitted us to assess that
the surface-exposed side chains of Pro145, Gly147,
and Gly148 are localized within the proximity of
Arg204. This spatial distribution led us to the initial
conclusion that Arg204, Pro145, Gly147, and Gly148
could likely form the binding region to MAb502.
Remaining positions variable in WB-negative
strains were located in the flexible tail of the NMR
structure of fHbp, making it difficult to speculate a
priori about their relevance for MAb502 binding.
Among residues varying either in WB-negative or
WB-positive alleles, we considered that Glu146,
Arg149, Ala174, and Lys230, due to their exposure
and closeness to Arg204, could form an accessory
part of the MAb502 epitope.
NMR data confirmed in large extent the prediction
based on the immunological data, as resonances of
Gly148, Arg149, and Arg204 were clearly perturbed
upon FAb502 interaction. The 15N resonance of
Glu146 is overlapped to other signals in the NMR
spectra, preventing us from definitively confirming
its inclusion into the epitope as predicted by
sequence alignment. In addition, NMR data sug-
gested the involvement of other amino acids, such as
Phe227, Gly228, and Glu233, otherwise unpredict-
able from sequence alignment because of their con-
servation among all the alleles analyzed. NMR data
also showed that the N-terminal flexible tail is not
involved in the interaction with FAb502. A number
of signals belonging to residues buried within the
fHbp interior were also perturbed upon FAb502
addition. These spectral changes might be a result of
structural rearrangements induced by fHbp binding
105A Protective Epitope of the Antigen fHbpmore than of direct contact with the antibody. This
behavior has been indeed observed in a number of
protein–protein complexes characterized by NMR.18
In order to derive from these NMR and immuno-
logical data a structural model of the complex and to
evaluate if all the 12 accessible amino acids identi-
fied by NMR mapping could constitute the MAb502
epitope, we modeled the fHbp–Fv502 complex by
molecular docking, from which two possible confor-
mations were obtained. The epitopes identified as
complexes 1 and 2 are largely overlapping, with 8
residues involved in the antigen–antibody interac-
tion for both models (Table 4). In both cases, Ala206
and Val207 are not directly involved in the interac-
tion with the antibody, suggesting that alterations
observed for their NH cross-peaks were likely due to
induced conformational changes.
The main difference between the two clusters lies
in the level of involvement of loop Glu146–Arg149.
These residues are all located in the contact area of
the first model, while only Glu146 experiences some
interaction with Fv502 in the second.
Overall, our results demonstrated the direct inter-
action of Arg204 with the antibody binding site and
evidenced the involvement of Glu146–Arg149 in the
formation of the antigen–antibody contact area,
albeit to a minor extent.
This epitope mapping study also provides indirect
information on the localization of the factor H
binding site. Here, we showed that MAb502 was
unable to prevent fH binding onto the fHbp surface
in contrast to JAR5. Although we cannot exclude
that such absence of inhibition was due to the lower
affinity of MAb502 to fHbp, these data seem to
suggest that the area targeted by this antibody is
distinct and sufficiently far away from the factor H
binding site to not compromise the formation of the
fH–fHbp complex. Our results fit the conclusions of
the epitope mapping study recently reported by
Beernink et al.,17 who observed fH binding inhibi-
tion by monoclonals recognizing Gly121 in N-
terminal domain of the protein and partially by the
ionic pair Lys180–Glu192 localized on the opposite
side of fHbpC with respect to Arg204.
The approach used here, which combined immu-
nological, FACS, WB, and NMR characterization,
was particularly powerful in defining the MAb502
epitope. These results represent the first step of an
experimental strategy in which vaccine candidates
can be designed to contain broad repertoires of
natural protective epitopes identified by molecular
mapping.Materials and Methods
Bacterial strains
Escherichia coli DH5 [F− 80lacZM15 (lacZYA-argF) U169
deoR recA1 endA1 hsdR17(rk
− mk
+) phoA supE44 thi-1 gyrA96
relA1 tonA] and BL21 Star (DE3) [F− ompT hsdSB (rB
− mB
−)
gal dcm rne131 (DE3)] (Invitrogen) were used as the cloning
strain and expression host, respectively. N. meningitidisstrains MC58, F6124, M2197, NZ98/254, and M4030
were previously described.8 Strains M01-240149 and
M01-240345 were isolated in the UK in 2001 (a kind
gift of Steve Gray, HPA, Manchester, UK). LNP17592 was
a W-135 strain, isolated in 2000 (a kind gift of Muhamed-
Kheir Taha, Institut Pasteur, Paris, France). Strains M6190
and M2937 were isolated in the United States in 1999 and
1996, respectively (kind gifts of Tanija Popovic, CDC,
Atlanta, GA).SDS-PAGE and WB analysis
Purified fHbp from MC58, the mutants Asn178→His,
Gly202→Lys, and Arg204→His, and the double mutant
Asn178→His Gly204→Lys (1 μg/lane) were analyzed by
WB. Samples were loaded onto 4%–12% NuPAGE poly-
acrylamide gel (Invitrogen) in Mes SDS running buffer
(Invitrogen) and transferred to a nitrocellulose membrane
(Bio-Rad).19
WB analysis was performed according to standard
procedures20 using anti-MC58 fHbp mouse polyclonal
antisera at a 1:20,000 dilution in phosphate-buffered saline
(PBS) containing 3% (w/v) skimmed milk and 0.01%
Triton and anti-fHbp MAb502 at a 1:5000 dilution
(0.34 μg/ml), followed by a 1:2000 dilution of horseradish
peroxidase-labeled antimouse immunoglobulins (DAKO).
The signal was developed with a Bio-Rad Opti-4CN
substrate kit. Scanning was performed using LabScan
(Pharmacia) and Imagemaster software (Pharmacia).FACS analysis
The analysis was determined using a FACScan flow
cytometer as described previously.8 Polyclonal sera were
tested at a 1:200 dilution. Antibody binding was detected
using a secondary antimouse antibody (whole molecule)
that was FITC conjugated (Sigma).
Serum bactericidal assay
Serum bactericidal activity (BCA) againstN. meningitidis
strains was evaluated as reported in Ref. 8. Pooled baby
rabbit sera have been used as a complement source
(Cedarlane or Pel-Freez).
Sequencing of Fv502
Approximately 5×106 MAb502-secreting hybridoma
cells were collected and homogenized via passage through
a 20-guage needle using an RNase-free 5-ml syringe. Poly
(A)+RNA was isolated using an Oligotex Direct mRNA
Mini Kit according to the manufacturer's instructions
(QIAGEN®). cDNA was produced via reverse transcrip-
tion using ∼200 ng of the poly(A)+RNA template, an
oligo-(dT)12–18 primer, and SuperScript™ II RT (Invitro-
gen). Reactions were incubated at 42 °C for 50 min,
followed by inactivation of the reverse transcriptase at
70 °C for 15 min. RNAwas removed from the reactions by
incubation with RNase H (Invitrogen) at 37 °C for 20 min.
The resulting cDNA was used as a template for PCR
amplification using Platinum® Taq DNA Polymerase High
Fidelity (Invitrogen) and various 5′ degenerate primers
and 3′ primers specific for FvH and FvL gene fragments
(Mouse Ig-Primer Set, Novagen).
PCRs for FvHwere incubated at 94 °C for 2min, followed
by 30 cycles of 94 °C for 1 min, 58 °C for 1 min 30 s, and
†NAMD was developed by the Theoretical and
Computational Biophysics Group in the Beckman Insti-
tute for Advanced Science and Technology at the
University of Illinois at Urbana–Champaign.
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completed the reactions. For the FvL, PCR was performed
using an additional primer complementary to the aberrant
light chain CDR3 (5′-ACC TAT TAC TGT CAG CAC ATT
A-3′) in molar excess to force truncation of the aberrant
cDNA product. PCRs for FvL were incubated at 94 °C for
2 min, followed by 30 cycles of 94 °C for 1 min, 62 °C for
1min, and 72 °C for 1min 30 s. A final extension at 72 °C for
10 min completed the reactions. Ten microliters of the PCR
products was analyzed on 1% agarose gel.
The PCR product of FvH was purified using a QIAprep
Spin Miniprep Kit (QIAGEN®). The PCR product of the
FvL gene fragment of the correct size (350–450 base pairs)
was excised from agarose gel and purified with a
QIAquick Gel Extraction kit (QIAGEN®).
The FvH and FvL purified fragments were converted to
blunt phosphorylated forms using an End ConversionMix
(Novagen) and were inserted into the EcoRV site of the
pSTBlue-1 Perfectly Blunt™ vector (Novagen) and trans-
formed into NovaBlue Singles™ competent cells (Nova-
gen) according to the manufacturer's instructions. Positive
colonies were selected by white/blue screening after
overnight growth, at 37 °C, on Luria–Bertani agar plates
containing ampicillin (50 μg/ml), X-gal (70 μg/ml), and
IPTG (80 μg/ml). White (positive) colonies, containing the
plasmid with insert, were incubated in 4 ml of Luria–
Bertani broth containing ampicillin (100 μg/ml) for 12–16 h
with vigorous shaking at 37 °C, andplasmidswere isolated
using a High Pure Plasmid Isolation Kit (ROCHE),
according to the manufacturer's instructions. BamHI and
HindIII digestion of ∼1 μg of the resulting plasmids and
resolution of the products via agarose gel electrophoresis
confirmed the presence of the appropriately sized inserts.
Positive clones were sequenced with T7 PR (TAA TAC
GAC TCA CTATAG GG) and pSTB rev (CCA CAC GTG
TGG TCTAGA GC) primers.
Nucleotide sequences of FvL and FvH are reported in
Fig. S1. The GenBank accession numbers are EU835941 for
FvL and EU835942 for FvH.
Preparation of FAb502
MAb502 was produced and purified as previously
described.8 MAb502 was dialyzed in 20 mM sodium
phosphate and 10 mM ethylenediaminetetraacetic acid,
pH 7.0, buffer and then incubated with immobilized
papain cross-linked on agarose support with respect to
the condition indicated in the kit specifics (Pierce code
20341) in order to generate the corresponding FAb
(FAb502). FAb502 was subsequently purified by affinity
chromatography using HiTrap Protein A Fast Flow (GE
Healthcare code 17-5079-01) in 20 mM sodium phosphate,
pH 7.0, buffer and eluted in 0.1 M sodium citrate, pH 5.0,
buffer. The fractions eluted were checked on SDS-PAGE
gel in nonreducing conditions, confirming the correct
molecular size of 50 kDa. The purest fractions were
pooled and dialyzed 1:100 overnight at 4 °C against
10 mM sodium phosphate, pH 7.0, buffer. The purified
FAb502 was then concentrated using a Centricon YM-30
(molecular weight cutoff=30,000) concentrator reaching a
final concentration of 0.1 mM. FAb502 was then tested in
WB against fHbp to assess the persistence of the activity.
15N-labeled fHbp cloning, expression, and purification
15N-labeled fHbpC protein fragment was expressed and
purified in E. coli as previously described.10 Purified 15N-
labeled fHbpC was concentrated using Centricon YM-10(molecular weight cutoff=10,000) to a final concentration
of 0.8 mM suitable for the NMR analyses.
NMR mapping of FAb502–fHbpC interaction
The interaction of FAb502 with 15N-labeled fHbpC was
investigated by NMR spectroscopy with 1H–15N HSQC
and CRINEPT experiments. The latter was recorded for
12 h, with a data size of 1024×232 points, a CRINEPT
transfer of 3.3 ms, and a recycle time of 1.1s. All the NMR
experiments were performed at 298 K on a Bruker Avance
900 spectrometer, working at 900.13-MHz frequency and
equipped with a cryogenically cooled probe.
Titrations were performed on 0.8 mM 15N-labeled
fHbpC protein samples with the unlabeled FAb502 up to
an fHbpC–FAb502 molar ratio of 1:1.
1H and 15N reso-
nance assignments for the fHbpC protein were already
available.10 All these samples were in 20 mM phosphate
buffer (90% H2O and 10% D2O) at pH 7.0.
Modeling of Fv502
The Fv fragment is the smallest FAb of the antibody
made of the variable domains of FvL and FvH. We deter-
mined the nucleotide sequences of FvL and FvH of
MAb502. The corresponding amino acid sequences (Fig.
S1) were then used to scan the Brookhaven Protein Data
Bank (PDB) in order to retrieve suitable templates for
modeling. Eighteen and 29 hits were retrieved for FvL and
FvH, respectively, with percentages of identity ranging
from 96% to 91% for FvL and from 82% to 74% for FvH.
Crystal structures of an antibody variable heavy chain
(PDB entry 32C2) and an antibody variable light chain
(PDB entry 1WEJ), showing 96%and 82%of identity to FvH
and FvL, respectively, of MAb502 were selected as tem-
plates. Models of FvL and FvH of MAb502 were obtained
with Swiss-PDB viewer21 software by alignment and
superimposition to the corresponding template chains
and used to assemble the whole Fv502. The resulting
model was refined by energy minimization and molecular
dynamics (MD). The molecule was solvated in a water box
of size 53.7×60.7×58.77, and ions were then added to
neutralize the resulting configuration. The system was
then equilibrated using the following schedule: (i) the
system was minimized for 300 steps, fixing the position of
the protein; (ii) the system was minimized for a further
300 steps followed by 1000 steps of MD, fixing the
position of water molecules and charged ions; (iii) the
system was minimized for a further 300 steps followed by
10,000 MD steps, fixing the position of the protein; and
(iv) the system was minimized for a further 300 steps
followed by a final MD simulation of 5×105 MD steps. All
simulations were performed using NAMD 2.622 and the
Charmm force field in the NPT ensemble at a pressure of
1 atm and a temperature of 300 K†. In all simulations, an
integration time step of 2 fs was used. Quality of models
was evaluated by using the program PROCHECK23 and
by visual inspection with the computer graphics program
VMD.24
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DockingcalculationswereperformedwithHADDOCK2.0.25
The docking calculations in HADDOCK are driven by
ambiguous interaction restraints (AIRs) between all
residues involved in the intermolecular interactions.26
Active and passive residues (Table S1) were defined accor-
ding to the HADDOCK protocol. Solvent accessibility was
calculated with the program NACCESS FvL.
As structures of the isolated proteins, 20 NMR confor-
mers of the fHbpC structure were used. For FAb502, struc-
tural models were generated as described above and the
lowest-energy structural model among those generated by
MD was chosen for docking calculations. Flexible regions
of the proteins were defined based on the active and
passive residues plus two preceding and following
residues.
In the initial rigid-body docking calculation phase, 1000
structures of the complex were generated, and the best 200
in terms of total intermolecular energy were further
submitted to the semiflexible simulated annealing and
final refinement in water. These 200 structures were then
clustered using a cutoff of 7.5 Å of RMSD among any
structure of a cluster. Only clusters containing at least 5
structures were taken and analyzed. Table S2 reports the
statistics calculated over the best fivemodels of each cluster
as well as over all the components of the cluster. Table S3
reports average pairwise RMSDs among the clusters.
Antibody inhibition and fH binding reactions
Bacteria were isolated in a single colony and then
inoculated in 7 ml of Mueller–Hinton broth plus 0.25% D-
glucose until the optical density reached 0.1. Cultures
were successively grown at 37 °C with 5% CO2 until the
optical density reached 0.6.
The culture was transferred to a sterile 50-ml conical tube
and washed with 40 ml of PBS plus 1% bovine serum
albumin (BSA) and then centrifuged at 3700 rpm (2908RCF)
for 10min. The pelletwas resuspended into 2ml of PBSplus
1% BSA [∼3 to 5×108 colony-forming units (CFUs)/ml].
Ten microliters of each MAb (final concentration=
50 μg/ml) or polyclonal serum (final dilution=1:400) was
added to an aliquot of 85-μl bacterial suspension, and the
mixtures were incubated at 37 °C for 10 min with gentle
shaking. Five microliters of human factor H (Calbiochem)
solution was added to achieve a final concentration of
50 μg/ml in the final reaction mixture. The samples were
incubated at 37 °C for 20 min with shaking. The mixture
was then centrifuged at 13,400RCF in amicrocentrifuge for
3 min to pellet the bacteria. After the aspiration of the
supernatant, the bacteria were resuspended in 100 μl of
PBS plus 1% BSA containing 1:100 dilution (final) goat
antihuman fH (Calbiochem). After incubation at room
temperature for 15 min, bacteria were pelleted and resus-
pended in 100 μl of PBS plus 1% BSA containing FITC-
conjugated donkey antigoat immunoglobulin G (Jackson
Immunoresearch) (final working concentration=1:100).
After 15 min at room temperature, bacteria were again
pelleted and resuspended in 1 ml of filter-sterilized,
freshly made 0.5% formaldehyde in 1× PBS for FACS
analysis, carried out as already described.5Accession numbers
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Factor H-binding protein is a 27-kDa lipoprotein ofNeisseria
meningitidis discovered while screening the bacterial genome
for vaccine candidates. In addition to being an important com-
ponent of a vaccine againstmeningococcus in late stage of devel-
opment, the protein is essential for pathogenesis because it
allows the bacterium to survive and grow in human blood by
binding the human complement factor H.We recently reported
the solution structure of the C-terminal domain of factor
H-binding protein, which contains the immunodominant
epitopes. In the present study, we report the structure of the
full-length molecule, determined by nuclear magnetic reso-
nance spectroscopy. The protein is composed of two independ-
ent barrels connected by a short link. Mapping the residues rec-
ognized by monoclonal antibodies with bactericidal or factor H
binding inhibition properties allowed us to predict the sites
involved in the function of the protein. The structure therefore
provides the basis for designing improved vaccine molecules.
Neisseria meningitidis, a Gram-negative bacterium that col-
onizes the upper respiratory tract of 10% of healthy human
population, is adapted to grow only in humans. With a fre-
quency of 1 in 100,000 population, the bacterium invades the
bloodstream and becomes a severe pathogen, causing sepsis
and meningitis. Vaccination with capsular polysaccharides
induces serogroup-specific protective antibodies.Meningococ-
cal capsular polysaccharide vaccines are available against sero-
groups A, C, Y, andW135 (1–3). On the contrary, the develop-
ment of a vaccine against serogroup B, still responsible for a
significant percentage of invasive diseases, has been protracted
due to the immunologic cross-reactivity of B polysaccharide
with human tissues. Recently, new perspectives to meningo-
coccal B (menB) prevention have been opened by the identifi-
cation of suitable protein-based vaccine antigens identified by
mining the bacterial genome (4). One of the most promising
antigens is the factorH-binding protein (fHbp).3 This is amem-
brane-anchored lipoprotein (3, 5, 6) that binds human factorH,
a negative regulator of the alternative complement activation
pathway.(7). Coating the bacterial surface with factor H allows
the bacterium tomimic a human tissue and avoid complement-
mediated lysis. fHbp is expressed by all the pathogenic strains of
N. meningitidis and can be classified in three distinct sequence
variants (5). This diversity has a remarkable impact on the
immunological properties of fHbp given that members of each
variant induce a strong protective immunity against meningo-
coccal strains carrying homologous alleles but are ineffective
against strains that express distantly related fHbp alleles.
A number of studies using monoclonal antibodies (8–11)
have identified residues involved in protective epitopes and fac-
tor H binding. Initially, Arg-204 and the cluster Glu-146–Arg-
149 were identified as targets of bactericidal monoclonal anti-
bodies elicited by the recombinant fHbp of variant 1 (v.1) (8, 9).
The same epitope was later shown to contain also Phe-277,
Gly-228, Lys-230, and Glu-233 (10). Recently, Beernink et al.
(11) used a panel of monoclonal antibodies obtained by immu-
nizing mice with all three variants of fHbp and identified Gly-
121 and Lys-122 as critical for binding by anti-v.1 antibodies.
Ser-216 was shown to be important for variant 2 (v.2), whereas
amino acid positions 174, 180, and 192 were shown to be key
residues to discriminate between variant 2 and variant 3 (v.3).
Although the molecular distribution of residues from 141 to
255 was appreciable onto the structure of C terminus domain,
whose solution structure was already solved (12), spatial
arrangement of Gly-121 and Lys-122 remained so far undeter-
mined. This incompleteness of information hampered a de-
tailed evaluation of the molecular distribution of variant-spe-
cific epitopes, as well as the opportunity to rationalize the
reported differences in the ability of monoclonals to induce
complement-mediated killing and inhibit the protein binding
to human factorH (11). In the present study, we determined the
structure of the full-length fHbp by NMR, which improves
the knowledge about the distribution of protective epitopes on
the protein surface and provides useful indications on the pos-
sible localization of the factor H (fH) binding site.
EXPERIMENTAL PROCEDURES
Sample Production and NMRMeasurements—Recombinant
fHbp v.1 (residues Met-7–Gln-255) was expressed in Esche-
richia coli as already described. Analytical gel filtration analysis
showed that the recombinant protein was eluted in fractions
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corresponding to a monomeric state of the molecule. Electros-
pray mass ionization-mass spectrometry spectrum indicated a
mass of 27281.43 Da, which corresponded to the cloned con-
struct. NMR spectra were acquired at 298 K on Avance 900,
700, and 500 MHz Bruker spectrometers, all equipped with a
triple resonance cryoprobe. The NMR experiments, used for
the backbone and the aliphatic side chain resonances assign-
ment recorded on 2H/13C/15N, 13C/15N, and 15N enriched and
on unlabeled fHbp samples, are summarized in supplemental
Table S1. The 1H, 13C, and 15N resonance assignments of fHbp
are reported in supplemental Table S2. All the amide protons of
the fHbp protein were assigned, with the only exceptions of
Val-8, His-26, Gly-202, and Gly-229. The assignment of the
aromatic spin systems was performed with two-dimensional
NOESY and total correlation spectroscopy maps acquired on
the sample dialyzed against deuterated buffer. Backbone dihe-
dral angle constraints were derived from 15N,13C,13C,13C,
and Ha chemical shifts, using TALOS (13). Standard errors of
values predicted by TALOS were used as allowed ranges of
variations in the dihedral angle constraints.
Distance constraints for structure determination were
obtained from 15N-edited and 13C-edited three-dimensional
NOESY-HSQC. Residual dipolar couplings have been meas-
ured in the presence of an external orienting medium consti-
tuted by a binary mixture of C12E5 (penta-ethylene glycol
dodecyl ether, 98%purity, Fluka) and neat n-hexanol (puriss.,
Fluka), which form a stable liquid crystalline phase made of
neutral aggregates (called bicelles) in the temperature range
from 298 to 312 K (14). The molar ratio of C12E5 to n-hexanol
was 0.96, and the C12E5/water ratio was 7% weight. One-bond
1H-15N coupling constants were measured at 298 K and 800
MHz by using the inphase anaphase (IPAP) method (15). A
total of 100RDCvalues have beenmeasured fromamide signals
not overlapped in the HSQC spectrum. Out of them, 73 RDC
values, derived from residues not experiencing R1 and/or R2
values outside the average values, were used for structure
calculations.
2987 meaningful proton-proton distance restraints (supple-
mental Fig. S4), together with 158  and 158  backbone dihe-
dral angles restraints, were included in structure calculations.
The exchangeability of the backbone amide hydrogenswith sol-
vent protonswas investigated through an 1H-15NHSQCexper-
iment performed on the protein previously extensively dialyzed
against deuterated buffer. Hydrogen bond constraints for the
slowly deuterium-exchanging amide protons of the -strands
were introduced at later steps of structure calculations.
Structure calculations were performed using the program
CYANA-2.1 (16). 900 random conformers were annealed
in 13,000 steps. The  tensor parameters were obtained with
FANTAORIENT, and they were optimized through iterative
cycles of PSEUDOCYANA until convergence (17).
The family of the best 30 structures in terms of target func-
tion was then subjected to restrained energyminimizationwith
the AMBER 10.0 package in explicit water solvent (18). The
distance and torsion angle constraints and the RDCs were
applied with force constants of 50 kcal mol1Å2 and 32 kcal
mol1 radians2, respectively. The conformational and ener-
getic analysis together with selected quality parameters from
PROCHECK-NMR, WHATIF (19, 20) analysis, and QUEEN
program (21) of the family of the best 30 structures are reported
in supplemental Table S3. The programMOLMOL was subse-
quently used for structure analysis (22). The root mean square
deviation values per residue of the restrained energy mini-
mization (REM) family of 30 conformers for the segment
14–255 are reported in supplemental Fig. S5.
15N R1, R2, and steady-state heteronuclear NOEs were meas-
ured with pulse sequences as described by Farrow et al. (23) R2
values were measured using a refocusing time of 450 s. In all
experiments, the water signal was suppressed with the “water
flip-back” scheme. Average R1, R2, and 1H-15N NOE values of
0.91  0.04 s1, 24.2  0.2 s1, and 0.70  0.03 are found,
respectively, at 500 MHz. The experimental relaxation rates
were used to map the spectral density function values, J(H),
J(N), J(0) following a procedure available in literature (24, 25).
RESULTS
The far-UVCD spectrum of fHbp had features characteristic
of a folded proteinwith a high content of-strands,whereas the
negative band at 198 nm, characteristic of random coil confor-
mation, was not present (data not shown). Consistently, the
1H-15N HSQC spectra show well dispersed resonances indica-
tive of an overall well folded protein (supplemental Fig. S1).
Heteronuclear relaxation rates, whose values are affected
by the dynamic properties of the molecule, were essentially
homogeneous along the entire polypeptide sequence, with
the exception of residues located at the C and N termini and
some loops. The correlation time for the molecule tumbling
(c), as estimated from the R2/R1 ratio, is 20.3  1.5 ns, con-
sistent with the molecular weight of the protein being in the
monomeric state.
The solution structure of the full-length fHbp consisted of
two domains, fHbpN (residues 8–136) and fHbpC (residues
141–255), composed of 10 and 8 antiparallel -strands, respec-
tively. fHbpN and fHbpC were connected by a five-residue
linker and had a topology of secondary structure elements as
shown in Fig. 1A, with an overall three-dimensional structure as
shown in Fig, 1B. Both domains are structurally well defined,
with only few loops showing some conformational disorder
(supplemental Fig. S2). From heteronuclear relaxation meas-
urements (supplemental Fig. S3), it appears that most of these
loop regions, and in particular, those including residues 85–90
and 118–123 located in the N-terminal domain, have signifi-
cantly lower heteronuclear NOE values as a consequence of
local motions in the ns–ps time scale. Consistently, they were
characterized by a very low number of long range 1H-1H NOEs
(supplemental Fig. S4), and consequently, their conformation
was less defined (supplemental Fig. S2).
The fHbpN domain has an elongated barrel-like structure
with a length of about 49 Å and a width of 22 Å. It is organized
in six antiparallel -strands of different lengths (2(45–50),
3(53–58), 5(72–84), 6(87–100), 7(104–111), 8(128–
136)), forming an extended -sheet, and two short -strands
(1(33–35) and 4(62–64)), which face the -sheet and a short
N-terminal -helix (16–21). In 50% of the family conformers, a
short-hairpin, including residues 114–116 (7) and 123–125
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(8), is observed between 7 and 8 (Fig. 1A), whose presence
is supported by the chemical shift index analysis.
The core of fHbpN is characterized by several hydrophobic
interactions that involve aromatic and aliphatic residues. In
particular, hydrophobic contacts are present between the resi-
dues clustered on one side of the -sheet (Leu-46, Leu-48 (2),
Ala-53 andTyr-57 (3), Phe-76, Phe-78 (5), Phe-96 andVal-98
(6), Ala-105 and Phe-109 (7), Ala-135(8) and those on the
two other -strands 1 (Leu-34 and Leu-36) and 4 (Leu-63),
determining the spatial proximity of the two regions and the
overall shape of the N-terminal domain. Further long range
interactions between residues Leu-
34, Thr-35, andAsp-133 andAla-135
maintain1 close to8, stabilizing the
overall structure. The three-dimen-
sional arrangement of the -strands
defines a hydrophobic core, which is
closed on one side by helix 1. Con-
tacts between some residues located
in 3, 4, and 5 and those in helix
1 are present that anchor such a
helix to the rest of the protein. The
latter interactions define the con-
formation of a long loop (segment
22–32), which is completely sol-
vent-exposed and rich in charged
residues. The latter loop, although
stabilized by the contacts of two
hydrophobic residues (Leu-24 and
Leu-31) with the rest of the protein,
experiences high conformational
disorder. Also, the region between 5
and 6, opposite to the N-terminal
helix, is solvent-exposed despite the
fact that it is rich in hydrophobic res-
idues (Fig. 1C).
The C-terminal domain fHbpC
is constituted by an eight-stranded
antiparallel -barrel (141–255),
whose strands are connected by
loops of variable lengths. The same
arrangement was previously found
in the solution structure of the same
domain in the isolated fHbpC
domain (12). The 310-helix present
in the solution structure of isolated
fHbpC domainis was still present in
the majority of 30 of the full-length
conformers, although shorter (141–
143) with respect to that observed
the isolated fHbpC (138–141). Siza-
ble variations for the backbone NH
chemical shifts of fHbpC domain in
the two constructs (0.25 ppm as
combined chemical shifts) were
observed on 7, 8, 9, 14, 15, and
16 (supplemental Fig. S6). The
largest differences were observed
for residues located in 7, 8, which formed a long disordered
tail in the isolated fHbpC domain. The other four -strands of
the C-terminal domain are located on the one side of the-bar-
rel and define the domain-domain interface. Interestingly, res-
idues located in 9, 14, 15, and 16 formed a hydrophobic
patch in fHbpC molecule. The present structure confirms our
previous insights on the role of this region of the -barrel (12).
The domain-domain interface, formed by about 850 Å2 of
buried surface, is stabilized by intermolecular contacts involv-
ing exclusively hydrophobic amino acids (Leu-106, Tyr-99,
Phe-129, Ile-134, N-terminal domain; Thr-155, Phe-157, Phe-
FIGURE 1. A, topology diagramof the fHbp protein. The-helices are represented by sky blue cylinders, and the
-strands are cyan arrows. N-term, N terminus; C-term, C terminus. B, ribbon diagram of fHbp. Secondary
structure elements are shown.-strands of the N-terminal domain are shown in cyan and helices are shown in
red, whereas -strands of fHbpC are shown in blue. C, the side chains of the hydrophobic residues involved in
interdomains contacts are shown as sticks in red, and pink. Contact surfaces are also reported. The other
hydrophobic residues are shown in blue. The charged residues are shown in green. The backbone is shown as
a ribbon.
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227, Leu-251, C-terminal domain, Fig. 1C). About 70 long range
interdomain NOEs were found that defined, together with the
RDCs, the reciprocal orientation of the domains.
DISCUSSION
Human complement is the first barrier of innate immunity
and kills infectious agents when they try to invade the blood-
stream (26). Todo this, it attacks anything that is not self. Factor
H and C4b are complement components that allow the system
to distinguish between invasive agents and self-tissues by coat-
ing the latter and avoiding the complement attack. During the
evolutionary battle for survival, virtually all pathogens have
foundmultiple and redundant ways to escape the complement-
mediated killing (27).One of themost popular strategies among
pathogens is to avoid complement by mimicking host surfaces,
covering themselves with factor H. fHbp of N. meningitidis is a
typical example of this class of molecules. By binding human
factor H, this protein allows the bacterium to survive and grow
in human blood and cause a terrible disease. This property,
together with the ability to induce in humans a strong antibody
response, makes this protein an attractive vaccine antigen able
to induce antibodies with a double function: killing the bacte-
rium by direct activation of the classical complement cascade
and preventing the formation of fH-fHbp complex on the sur-
face of the bacterium.
Based on the knowledge of the complete structure of fHbp,
we can identify the location of the variable amino acids (Fig.
2A), the residues involved in binding protective monoclonal
antibodies (Fig. 2B), the region bound by antibodies against
variant 1 (Fig. 2C), the region bound by antibodies against var-
iant 2 (Fig. 2D), and the residues recognized by the antibodies
that inhibit factor H binding (Fig. 2E). The variable residues
(Fig. 2A) cluster in the upper part of the molecule. This is con-
sistent with a model where the protein is anchored to the bac-
terial cell wall through the palmitic acid extension of Cys-1 (5)
and exposes the upper part to the outside, where it is under the
selective pressure of the immune system. Accordingly, the
amino acids known to be part of epitopes (8, 9, 10, 11) are all
localized in correspondence of the zone of higher variability
(Fig. 2B). Arg-204, Gly-121, and the loop formed by Glu-146
until Arg-149 were identified as involved in the formation of
bactericidal v.1 epitopes (8, 9, 11). Arg-204 is located in the loop
between 12 and 13, whereas the segment 146–149 corre-
sponds to the region connecting the two fHbp domains and
containing the second short helix2. Gly-121, which was local-
ized in the disordered region of the isolated fHbpC domain,
now occupies the loop between 7 and 8 strands. NMR-
driven epitope mapping carried out on the isolated fHbpC
domain identified Phe-141, Lys-199, Arg-204, Glu-146–Arg-
149, Phe-227, Lys-230, and Glu-233 as part of the same epitope
recognized by the bactericidal monoclonal antibody Mab502
elicited by fFbp v.1 (10). The distribution of these residues on
the full-length protein supports the hypothesis that the fHbpC
domain contains the major part of the native epitope, which
consists of all those residues still accessible in the whole fHbp
with the exception of Phe-227 and Glu-233, which are now
shielded by the presence of the N-terminal domain. Epitopes of
v.2 and v.3 have recently been shown to include residues in
positions 174, 216, 180, and 192 (11). Although none of the
corresponding monoclonal antibodies were bactericidal indi-
vidually, nevertheless some pairs of them were able to perform
FIGURE 2. A, variability profile of the three fHbp variants. Conserved amino acids
are colored in blue, conservative substitutions are colored in gray, and variable
amino acids are colored in green. B, distribution of amino acids recognized by
monoclonal antibodies (Mabs) raised against v.1 (purple) and v.2/v.3 (green). C
andD, molecular areas recognized by the bactericidal pairs of monoclonal anti-
bodies against v.1 (orange) and v.2 (gold) (11). E, molecular distribution of fHbp
residues recognized by monoclonal antibodies inhibiting (red), partially inhibit-
ing (orange), and not inhibiting (green) the fH binding (11).
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meningococcal killing when combined. The samewas true for a
pair of monoclonal antibodies raised against v.1 (11). We tried
to identify the fHbp regions targeted by these pairs of bacteri-
cidal monoclonal antibodies, placing residues recognized by
each component at the center of a molecular area of 950 A2, a
value chosen as the representative value of the average size for a
protein conformational epitope (28–31). The interesting
observation that the bactericidal epitopes crucial for the killing
of v.1 and v.2 are only partially overlapping suggests that it may
be possible to engineer molecules containing epitopes of all
variant proteins (Fig. 2,C andD). Finally, Fig. 2E shows that the
residues recognized by the monoclonal antibodies that inhibit
factorHbinding (11) are located In the upper part of both in the
N-terminal and in theC-terminal part of themolecule, suggest-
ing that this region is involved in the interaction with factor H.
In conclusion, the complete structure of fHpb allowed us to
map residues involved in important functions, such as binding
to factor H and eliciting bactericidal antibodies, and provides
the basis to understand the molecular mechanisms behind the
function of this importantmolecule. The structuremay be used
to design improved vaccine antigens.
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5.1 Abstract 
The factor H binding protein (fHbp), a 27-kDa membrane-anchored lipoprotein 
of Neisseria meningitidis, is the major component of a universal vaccine 
against meningococcus B. Moreover the protein is essential for pathogenesis 
because it allows the bacterium to survive and grow in human blood by binding 
the human complement factor H (hfH).  
In this study, we used nuclear magnetic resonance spectroscopy to investigate 
the interaction between fHbp and a construct of the factor H comprising 
domains 5, 6 and 7 (hfH567). 
The data show that the hfH567 binds an extensive region of fHbp which 
involved both N- and C-domains of the protein and that residues previously 
targeted as essential for the binding with MAb502 are not affected by the 
presence of hfH. 
5.2 Introduction  
Neisseria meningitidis, a Gram-negative bacterium that colonizes the upper 
respiratory tract of 10% of healthy human population, is adapted to grow only 
in humans. With a frequency of 1 in 100,000 population, the bacterium invades 
the bloodstream and becomes a severe pathogen, causing sepsis and 
meningitis. Vaccination with capsular polysaccharides induces serogroup-
specific protective antibodies. 
Meningococcal capsular polysaccharide vaccines are available against 
serogroups A, C, Y, and W135 (1, 2, 3). On the contrary, the development of a 
vaccine against serogroup B, still responsible for a significant percentage of 
invasive diseases, has been protracted due to the immunologic cross-reactivity 
of B polysaccharide with human tissues. Recently, new perspectives to 
meningococcal B (menB) prevention have been opened by the identification of 
suitable protein-based vaccine antigens identified by mining the bacterial 
genome (4). 
One of the most promising antigens is the factor H-binding protein (fHbp), 
whose solution structure was recently determined by NMR spectroscopy  (5). 
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This is a 27kDa membrane-anchored lipoprotein (6, 7) present on the surface 
of all strains of N. meningitidis and elicits protective bactericidal antibodies. 
fHbp binds human factor H (hfH), a negative regulator of the alternative 
complement activation pathway (8). The bacterium is able to cover its surface 
with factor H allowing mimicking a human tissue and avoiding complement-
mediated lysis. 
Factor H is a single polypeptide chain plasma glycoprotein (155 kDa), 
composed of 20 repetitive units of 60 amino acids (9), named short consensus 
repeats (SCR) or complement control protein modules (CCP). The 3D 
structure of several SCRs have been determined, showing a globular structure 
with six-stranded antiparallel β-sheets connected with loops and turns (10, 11, 
12). 
Recently Tang and co-workers solved the x-ray structure of the complex 
between fHbp and a construct of hfH including domains 6 and 7 (hfH67) (13); 
this study pointed out the crucial role of the sixth domain for the interaction. In 
particular they defined two residues on fHbp (Glu 218 and Glu 239) located on 
the sixth domain as absolutely required for the binding. 
In this work we investigated through NMR measurement on the interaction 
between fHbp and the factor H construct comprising domains 5, 6 and 7 
(hfH567). Residues involved in the interaction have been mapped by NMR 
titrations with the hfH567 on fHbp. 
The data showed that hfH567 recognizes an extended area of fHbp, including 
both N- and C-domains. 
5.3 Methods 
The interaction of hfH567 with 15N-labelled fHbp was investigated by NMR 
spectroscopy with 1H–15N TROSY-HSQC experiments. All the NMR 
experiments were performed at 298 K on a Bruker Avance 900 spectrometer, 
working at 900.13MHz frequency and equipped with a cryogenically cooled 
probe. 
Investigation on the interaction between factor H binding protein and domains 
5, 6 and 7 of human factor H 
_____________________________________________________________________ 
 73 
Titrations were performed on 0.2 mM 15N-labelled fHbp protein samples with 
the unlabelled hfH567 up to an fHbp–hfH567 molar ratio of 1:1. 1H and 15N 
resonances assignment for the fHbp protein was already available (5). All the 
samples used were in 20 mM PBS (90% H2O and 10% D2O) at pH 7.0. 
Solvent accessibility for fHbp residues was calculated with the program 
NACCESS (14); only residues with a global solvent accessibility larger than 
40% were considered for the mapping. 
5.4 NMR mapping of the hfH567-fHbp interaction 
The interaction between fHbp and a construct of the human factor H 
comprising domains 5, 6 and 7 (hfH567) was investigated through NMR 
spectroscopy, by analyzing the perturbations caused in the 1H–15N TROSY-
HSQC spectra of 15N-labelled fHbp upon addition of unlabelled hfH567 up to a 
fHbp:hfH567 ratio of 1:1. 
Chemical shift variation of NH cross peaks observed in the 1H–15N TROSY-
HSQC spectra upon addition of hfH567 indicated that the two proteins are 
interacting. 
The fHbp-hfH567 complex exchanged with the free proteins at rates slower 
than the resonance frequency differences between the two forms (i.e., in the 
range of milliseconds).   
Residues of fHbp experiencing different chemical shift upon addition of hfH567 
are shown in Figure 1A and listed in Table 1. They comprise an extensive 
region which involves both the N- and C-terminal domains of fHbp. Notably, 
surface-exposed residues (magenta in Figure 1), located in the linker 
connecting the N- and C-domains of fHbp (Thr139, Ser140, Phe141, Asp142 
and Lys143) and several buried residues located at the domain-domain 
interface of fHbp (Gln97, Tyr99, Gln101, His103, Phe129, Gly132, Ala135, 
Ile226, Gly236, Ser237, His248, Ile249, Gly250 and Leu251 shown in red in 
Figure 1) result perturbed by the addition of hfH567, suggesting that a 
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molecular rearrangement of fHbp occurs during the formation of the fHbp-
hfH567 complex.  
 Previous studies have shown that residues Gly121 and Lys122 are 
recognized by antibodies that inhibit hfH binding as JAR3 and JAR5 (15). 
These residues are solvent-exposed and they are located in the loop between 
β7 and β8 of the N-terminal domain of the molecule. In agreement with ELISA 
data, spectral perturbations were observed for their NH cross peaks upon 
addition of hfH567 to fHbp. We have instead recently demonstrated by FACS 
experiments (16), that the hfH-hfHbp interaction cannot be hindered by the 
monoclonal antibody MAb502 binding to fHbp. Residues involved in the 
interaction with MAb502 are Arg204, Glu146-Arg149, Ala174, Lys230 and 
Glu233. The latter residues are indeed not affected by hfH567 binding 
confirming that hfH567 interacts in a different region with respect to MAb502. 
 Recently, the crystal structure of the complex of fHbp with a construct of 
human factor H including domains 6 and 7 (hfH67) was determined (13). The 
hfH-fHbp complex is held together by extensive interactions between both the 
N- and C-terminal domains of fHbp and the domain 6 of hfH, while fewer 
contacts were found between fHbp and domain 7 of hfH. In particular two 
residues (Glu218 and Glu239, located on β14 and β15 of fHbp, respectively) 
were found to be essential for the interaction with the domain 6 of hfH67.  
 The total number of perturbed, surface-exposed residues in solution 
define a larger contact area with respect to that found in the crystal, but still 
contains all the residues located at the interface between hfH67 and fHbp, 
indicating that also in solution and in the presence of a longer construct of hfH, 
the same interacting surface of the fHbp is maintained (Figure1).  
The higher number of residues perturbed by the presence of hfH567 with 
respect to the crystal complex with hfH67 can be justified by a model of 
interaction for fHbp-hfH567 complex in which the reciprocal orientation of fHbp 
N- and C-domains changed if compared with the structure of the free fHbp and 
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in which domain 5 of hfH, absent in the crystal, made contacts with residues 
Ile198, Lys 199 and Asp142.  
 
 
Table 1. Amino acids of fHbp whose amide signals experience different 
chemical shift (> 0.1 ppm) upon the addition of hfH567. B=buried; E=exposed 
as it results from the solvent accessibility calculated with the program 
NACCESS (14). 
 
Residues  
B Leu31,Gln32,Leu36,Ser39,Val40,Glu44,Tyr57,Asn64,Ser74,Phe76,Phe78,Arg80 
Gln81,Ile82,Ile89,Ser93,Phe96,Gln97,Val98,Tyr99,Gln101,His103,Thr107,Phe109,
Gln110,Thr111,Ile114,Asp116,Phe129,Gly132,Ala135,Tyr152,Lys165,Gly177, 
Gly179,Ala196,Ile198,Ala206,Val207,Gly210,Val212,Gly220,Leu224,Gly225,Ile226,
Gly236,Ser237,Ala238, Thr242,His248,Ile249,Gly250,Leu251 
E Asp37,Gln38,Arg41,Lys42,Asn43,Lys45,Thr56,Glu83,Gly86,Leu91,Glu95,Glu112, 
His119,Gly121,Lys122,Val124,Lys126,Arg127,Gln128,Arg130,Thr139,Ser140,Phe1
41,Asp142,Lys143,Asp160,Gly163,Glu188,Lys199,Ser211,Leu213,Lys219,Ser221,
Ser223,Lys241 
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Figure 1. (A) Residues experiencing chemical shift differences mapped on the 
molecular surface of the free fHbp. Surface-exposed and buried residues, 
whose amide NMR signals were perturbated (> 0.1 ppm) upon addition of 
hfH567, are shown in magenta and red, respectively. Residues whose amide 
signals were not perturbated upon addition of hfH567, prolines, and residues 
that could not be accurately analyzed due to spectral overlap, are in gray. (B) 
Residues mapped on the molecular surface of the free fHbp (PDBID 2KC0) 
and located at the interface of the fHbp-hfH67 complex in the crystal structure 
are shown in magenta. 
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6.1 Abstract  
Antibodies to factor H (fH) binding protein (fHbp), a meningococcal vaccine 
antigen, activate classical complement pathway serum bactericidal activity 
(SBA) and block binding of the complement inhibitor fH. To understand these 2 
functions in protection, it results very interesting to investigate the interactions 
of human complement and anti-fHbp monoclonal antibodies (mAbs) with 
encapsulated Neisseria meningitidis (1). In this work we focused on the study, 
through NMR measurements, of the interaction between fHbp and mAb JAR4, 
which cross-reacted with both variant 1 and 2 fHbp in 95% of strains and 
elicited human complement-mediated, cooperative bactericidal activity with 
other non-bactericidal anti-fHbp mAbs.  
Our data showed that JAR4 recognized a well defined area on the N-domain of 
fHbp, demonstrating that this region, previously indicated as involved on JAR4 
binding (2), is actually implicated in the interaction with this mAb. 
6.2 Introduction 
Meningococcal factor H-binding protein (fHbp) is a promising vaccine 
candidate that is part of two vaccines in clinical development (3). 
The protein binds human factor H (hfH) (4, 5) which is a down-regulatory 
molecule in the complement pathway (6). 
By the binding of hfH on the surface of Meningococcus, the latter avoid the 
complement system by mimicking host surfaces and survive in the in human 
blood causing meningitis. 
Antibodies against fHbp both activated the classical complement pathway and 
also block the binding of hfH to the surface of the bacteria (1, 7). Among 
different strains of N. meningitidis, fHbp exists in several antigenic variant 
groups based on antibody cross-reactivity and amino acid sequence identity. 
These fHbp groups have been designated variant 1, 2 or 3 by Masignani et al. 
(8). 
A panel of anti-fHbp mAbs were previously characterized (9); several of the 
mAbs were bactericidal against strains with relatively high expression of fHbp 
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but were not bactericidal against other strains with lower expression of fHbp. 
Moreover a huge number of mAbs, showed a bactericidal activity only if 
combined with others mAbs. One example is JAR4, an antibody isolated from 
a mouse immunized with recombinant variant 1 fHbp. It indeed elicited a 
cooperative activity in combination with mAb JAR3 (1, 7), but the mechanism 
through which this occurs is not clear. 
In fact, while mAb JAR3 was bactericidal only against strains with relatively 
high fHbp expression, mAb JAR4 was not bactericidal against any strains. The 
low-expressing fHbp strains required both mAbs together for complement-
mediated bactericidal activity. 
JAR3 and 4 bind to non-overlapping epitopes because, as shown by ELISA, 
neither MAb inhibited binding of the other mAb to fHbp. JAR3 but not JAR4 
also inhibited binding of purified fH to N. meningitidis (5). 
From filamentous bacteriophage libraries containing random peptides that 
were recognized by JAR4, a consensus tripeptide  DHK that matched residues 
25–27 in the N-terminal domain of fHbp was identified. 
Since DHK was present in both JAR 4-reactive and non-reactive fHbps, the 
tripeptide was necessary but not sufficient for reactivity.  
Collectively, the data indicated that the epitope for JAR4 was discontinuous 
and involved DHK stretch, together with a three residues stretch (YGN) 
beginning at position 57 (2). 
Thus, the region of fHbp encompassing residues 25–59 in the N-terminal 
domain is important for eliciting antibodies that can cooperate with other anti-
fHbp antibodies for cross-reactive bactericidal activity against strains 
expressing fHbp from different antigenic variant groups. 
In our NMR study we demonstrated, through NMR titration, this evidence. 
Indeed the region encompassing the first 60 aa was perturbed upon addition of 
JAR4, while the C- terminal domain of fHbp is not affected by JAR4 binding. 
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6.3 Methods 
The interaction of the antigen binding fragment (FAb) of JAR4 (FAb4) (50 kDa) 
with 15N 2H labelled fHbp was investigated through NMR spectroscopy with 
1H–15N TROSY HSQC experiments. All the NMR experiments were performed 
at 298 K on a Bruker Avance 900 spectrometer, working at 900.13MHz 
frequency and equipped with a cryogenically cooled probe. 
Titrations were performed on 0.15 mM 15N 2H labelled fHbp sample with the 
unlabelled FAb4 up to an fHbp–FAb4 molar ratio of 1:1.45. 
All the samples used were in 20 mM PBS (90% H2O and 10% D2O) at pH 7.0. 
6.4 NMR mapping of the JAR4-fHbp interaction 
The interaction between fHbp and the JAR4 was investigated through NMR 
titration, by analyzing the chemical shift perturbations caused in the HSQC 
spectra upon addition of JAR4. 
Residues whose NH cross-peaks were affected by presence of JAR4 all 
belonged to the N-domain of fHbp, forming a clustered region of interaction. 
These residues include the first α-helix, the loop connecting α1 and β1 and the 
β strands β1, β2, β3, β4, β5. 
The mapping of residues involved in the binding with JAR4 is shown on figure 
1 and included also the tripeptide DHK (25-27) and YGN (57-59), whose 
resonances were clearly perturbed in the presence of FAb4. 
This work is still in progress. Previous immunological data have been now 
demonstrated and the next step of this project will regards the investigation of 
the interaction between the fHbp and other mAbs. 
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Figure 1. Aminoacids whose NMR signals were perturbed upon the addition  
of FAb4 to the NMR sample. They are indicated as solid spheres in 
correspondence to their backbone nitrogen atoms. In green are indicated DHK 
(25-27) and YGN (57-59) segments. 
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General Discussion and Future Perspectives 
 Structural biology is a branch of the life science which provides a 
detailed analysis at atomic level of the structure of biological macromolecules, 
how they acquire the fold they have and how alterations in their structures 
affect their function, with the ultimate goal of investigating the relationship 
between these two latter aspects. 
This subject is of great interest because macromolecules carry out most of the 
functions of cells and because it is only by arranging into specific three-
dimensional shapes that they are able to perform their physiological roles. 
The high resolution three-dimensional structure at the atomic level of a 
protein can be solved through X-ray crystallography or through NMR 
spectroscopy. The latter method has the advantage of studying proteins under 
conditions which can be as close as possible to their physiological state.  
With NMR spectroscopy, a complete description of the molecule can be 
obtained, ranging from the folding process to the internal motions of the 
protein, all aspects which are essential for a deep understanding of the 
biological function. In addition, the recent development of methodology and 
algorithms for the quick determination of structures represent an enormous 
advance in structural biology in solution. The newly solved genomes from an 
increasing number of organisms bring an enormous number of new proteins to 
our knowledge, the majority of which have unknown function. This huge 
collection of new data needs to be analyzed and further investigated. In 
particular the structural and dynamic characterization of proteins is essential to 
shed light on their physiological functions.  
Structure determination has already proven useful for the identification and 
evaluation of chemical leads (1). The number of high-resolution structures 
available in public databases today exceeds 30,000 and will definitely aid in 
structure-based drug design (2) and in improving drug potency and selectivity 
(3).  
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Using high resolution structures, antigens can be designed to cover more 
efficiently the majority of the strains of a pathogen. 
By engineering antigens amenable for use in combination vaccines, 
immunization regimens can be simplified. By knowing which parts of an 
antigen must be retained to preserve basic characteristics and which can be 
altered, vaccine antigens can be modified more rapidly in response to 
changing epidemiology. 
 My work of thesis was developed in collaboration with Novartis-
Vaccines and it was focused, in the frame of the extensive project concerning 
the development of a universal vaccines against Meningococcus B (MenB), on 
structural studies on new antigen candidates against Neisseria Meningitidis. 
In the year 2000 Novartis laboratory published the use of the genomic 
sequence of a particular strain of MenB (MC58 strain) to discover novel 
antigens capable of inducing protection against serogroup B of N. Meningitidis 
(4). 
Factor H binding protein (fHbp) is currently the more effective antigen 
discovered while screening the bacterial genome (5, 6) able to induce 
bactericidal antibodies, so the most important constituent of a universal 
vaccine. 
The peculiarity of fHbp consists in its double function: killing the bacterium by 
direct activation of the classical complement cascade and preventing the 
formation of the complex human factor H(hfH)-fHbp on the surface of the 
bacterium (7, 8). 
During my PhD I focused my attention on structural and dynamic 
characterization of fHbp. This study had a big scientific impact because not 
only allowed to solve a structure unknown so far, but also because it is the 
starting point for following important studies, like the investigation of the 
interaction with several monoclonal Antibodies or other important human 
proteins, as the hfH. 
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NMR studies turned out to be crucial for a deep investigation of the 
problem and provided important information also for future designing of new 
vaccine antigens. 
Thanks to the improved NMR technology, the avaibility of high magnetic fields 
and new kind of NMR experiments like TROSY and CRINEPT, which allow the 
structural characterization of proteins with high molecular weight, it was 
possible to determine structures like fHbp, of more than 250 residues. 
We defined two different domains of fHbp with a β barrel like conformation, 
connected by a five residue linker and from mobility data the value of the 
correlation  time (τc) for the molecule tumbling (estimated of 20.53 ± 1.5 ns) 
confirms that the protein rotates in solution as a single entity, being in a 
monomeric state. 
 The discovery of this structure has given the bases for a series of 
analysis, focused on the study of the interaction of fHbp with other important 
macromolecules, crucial targets of the immunity system, as for example 
monoclonal Antibodies (mAbs) and the hfH. 
 
The structural approach applied to vaccinology may help the rational 
engineering  of future antigens; structural studies of antigen epitopes may help 
the understanding of the molecular nature of epitopes and their mechanisms of 
action. Moreover the application of the structural biology to the vaccinology 
field allowed to investigate on the interaction Antigen-Antiboby, process which 
is a crucial step for the immunity response. 
 The latter aspect was firstly investigated: the study of the interaction 
between the monoclonal Antibody MAb502 and the C-terminal domain of fHbp 
(fHbpc) allowed to define critical residues for the binding. 
Through NMR indeed, it is possible to monitor the NH chemical shift variation 
of residues which are directly involved in the interaction with MAb502. 
The information obtained together with biological data have been fundamental 
to define a conformational epitope within a well define area on fHbpc . 
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Besides NMR technique was used to study the interaction of fHbp full 
length and a construct of factor H comprising domains 5, 6 and 7. 
The importance of this study consists on the fact that the binding with hfH is a 
form of resistance of MenB to the immunity system, because covering its 
surface with hfH, fHbp mimicks the host surface, avoiding the complement 
attack. 
Especially in this case NMR spectroscopy resulted to be essential because it 
was possible, at high magnetic field and with the use of TROSY experiments, 
to study a complex of about 80 kDa. 
Moreover this investigation confirmed the fact that residues involved in binding 
with hfH do not overlap with the epitope for MAb502, supporting the previous 
theory that MAb502 is a monoclonal Antidoby not inhibiting-hfH binding. 
 
 My project then concentrated on the study of the interaction with other 
variant-specific mAbs, which carry on their bactericidal function only in 
presence of other mAbs, as for example the anti-fHbp mAb JAR4. Also in this 
case this study allowed to map the  region of interaction on fHbp. 
With respect to expression of fHbp, N. meningitidis strains can broadly 
be subdivided into 2 groups: strains associated with high level of expression of 
fHbp and strains associated with low level of expression of fHbp (5). 
Several data underscore the correlation between low expression of fHbp by a 
strain and the requirement for >1 anti-fHbp mAb to elicit bactericidal activity 
(5). 
Based on this statement, we started to investigate through NMR 
measurements on the mapping of the interaction between fHbp and JAR4. 
This kind of analysis will proceed with the investigation, by NMR experiments, 
of the interaction with other mAbs to define the bactericidal synergy. 
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The MenB vaccine, containing as principal component fHbp variant 1, can be 
improved in order to increase the immunological coverage using engineered 
fHbps (also called patches) that display epitopes of different variants.  
Several mutants containing different combination of epitopes of variant 1 and 2 
have been so far expressed by site-directed mutagenesis, introducing groups 
of point mutations into the fHbp v1 scaffold. These mutants have been named: 
P2S, P5A, P5E, P8B, P9C, P10A, P10B, P11B, P11I and P13B. Multiple 
sequence alignment of wild-type fHbps and various engineered fHbps 
(patches) is reported on figure 1. 
The impact of respective fHbp sequence modifications on the overall structure 
is addressed using various analytical tools.  
Results may help to improve interpretation of different protective properties 
found for various engineered fHbps when studied in vivo from a more 
structural point of view and potentially allow further optimization of the antigen. 
Preliminary NMR studies, through 1H-15N HSQC experiments analysis, allowed  
to assemble fHbp mutants on the basis of the similairty of the their HSQC 
specta, to further understand if a correlation between groups of mutants with 
similar HSQC profile and comparable immunological activity exists. 
From the comparison fHbp wild-type - fHbp patch HSQCs, it appears that most 
of the NH-cross peaks chemical shifts are maintained, however easily  
reassignable, especially at the N-domain. 
Together with respective immunization studies (using various patches in 
different vaccine formulations), the data may help to better understand the 
potential impact of structural changes within engineered fHbps on their cross-
protective immunity and potentially allow a further optimization of the antigens. 
 
Future additional structural and dynamic studies will be expand to other 
variants of fHbp, to further investigate on the interaction between these 
variants and variant-specific mAbs. 
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During the last part of my PhD my attention will be devote on the study of 
variant 3 (v3). In difference with variant 1, variant 3 results less stable, in fact 
the chemical shifts of some NH groups in the HSQC spectra are different for 
different samples; this indicates that the structure of the protein slightly 
changes according to the protein preparation. The most significant changes in 
chemical shift can be assigned to the residues of the N and C-terminal regions. 
These regions are also the most affected by degradation in time. 
 
Up to now 85% of the backbone atoms have been assigned. Most of residues 
which are not assigned yet are located in loop regions of the β barrel at C-
terminal domain, as indicated on a model of fHbp v3 shown on figure 2. 
Comparison of the secondary structures elements of variant 1 and 3, the latter 
estimated by the Chemical Shift Index (CSI) analysis (9), showed that some β 
strands in variant 3 are shorter than β strand on variant 1. 
Sequence similarity is quite high between v1 and v3 (around 63%). 
 
The final goal of the global project is to improve the vaccine preparation, 
in order to increase the immunological coverage to the majority of MenB 
strains, using engineered fHbps that display epitopes of different variants, 
aimed to obtain a single chimeric molecule. 
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Figure 1. Multiple sequence alignment of wild-type fHbps and various 
engineered fHbps (patches). Points of mutation are indicated in circles. 
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Figure 2.  A Structure of fHbp variant 1. B Model of fHbp variant 3 obtained 
with MODELLER using the NMR structure of fHbp v1 as template. Residues 
not assigned yet are indicated as green sphere in correspondence to their 
nitrogen atom. 
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